The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030

Lowest Price Guaranteed
From USD 4,899
Published
January 2020
Pages
641
View Count
2393
Order Now

Overview
Contents
Segmentation
Request Sample
Request Customization
Free Insights

Example Insights

Overview

The human body is known to harbor numerous communities of microbes, including both beneficial and harmful species, which are collectively referred to as the microbiota. Likewise, the ecological system of commensal, symbiotic, and perhaps pathogenic microorganisms that reside within a host system is called the microbiome. Research insights, generated primarily from the Human Microbiome Project (2009) and other independent studies, have demonstrated that an imbalance in the microbiome (also known as dysbiosis) may lead to the development of several chronic clinical conditions, including Clostridium difficile infections (CDIs), irritable bowel syndrome (IBS), diabetes, Crohn’s disease and ulcerative colitis. Given the role of the microbiota in both disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine. The growing popularity and interest in the therapeutic potential of the microbiome is evident across scientific literature; commonly cited terms in this context include microbiome, microflora, microbiota, fecal microbiota therapy (FMT), microbiome diagnostics, or human microbiome, as observed on the NCBI’s PubMed portal, over the last three years.

Over time, the efforts of industry stakeholders and clinical researchers in this domain have led to the discovery of novel therapeutic strategies, including the establishment of a gut-brain axis, involving the human microbiome. Despite the evident increase in interest (of therapy developers and investors alike) in this field of research, there are currently no approved microbiome-based drugs / therapy products available in the market. However, there is a FMT in the market that is designed to modulate the microbial population within the gut for the treatment of recurrent CDIs. This treatment has been shown to be particularly beneficial to those who are non-responsive to standard-of-care therapies. In addition, a number of microbiome diagnostic tests are available for the detection of digestive and gastrointestinal disorders, inflammatory diseases and certain oncological indications. Further, several technology developers have started using next-generation sequencing techniques and other versatile bioinformatics tools for the characterization of important species of gut microflora. It is also worth mentioning that, in the last 4-5 years, there has been a marked rise in the number of new entrants in this field. Interestingly, several big pharma players have also become actively involved in this domain. Given the fact that there are several candidate therapies in late phases of clinical development, the microbiome-based medical products market can be expected to witness substantial growth over the coming decade.

Scope of the Report

‘The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based medical products (including therapeutics, diagnostics and FMTs), over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:

A detailed assessment of the current market landscape of microbiome therapeutics, providing information on drug / therapy developer(s) (such as year of establishment, location of headquarters and company size), clinical study sponsor(s) or collaborators, phase of development (clinical, preclinical, and discovery stage) of product candidates, type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designations (if any). In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.
Elaborate profiles of key players (established after 2005) that are engaged in the development of microbiome therapeutics (which are presently in both preclinical and clinical stages of development); each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.
A discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research, along with [A] a detailed review of the current market landscape of microbiome diagnostic tests, including the information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis, [B] brief profiles of popular diagnostic developers, and [C] an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.
A review of the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, therapy procedure, route of administration, important clinical guidelines, regulatory guidelines and insurance coverage, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on FMT developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.
A detailed business portfolio analysis based on an attractiveness and competitiveness (AC) framework, highlighting the current market attractiveness and existing competition across the most popular disease indication(s) for which microbiome therapeutics are under investigation.
An analysis of the varied microbiome-focused initiatives of big pharma players (out of top 20 established pharmaceutical players), featuring a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
An analysis of the start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics, featuring heat map representation based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.
An assessment of the most commonly targeted therapeutic indications and details of microbiome-based drugs that are being developed against them, highlighting key epidemiological facts about specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.
An analysis of the investments made, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings, at various stages of development in start-ups / small-sized companies (established in last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics.
An elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics, along with [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on year of establishment, location of headquarters, and company size, [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details, and [D] an insightful Harvey ball analysis of key considerations that need to be taken into account by industry stakeholders while selecting a suitable CMO / CRO partner.
An assessment of the emerging role of big data, highlighting efforts focused on the development and implementation of various algorithms / tools to analyze data generated from microbiome research along with [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.
An informative case study on the various other applications of microbiome products, such as agriculture, animal health, plant health, food products, featuring a list of nearly 80 products, including probiotic supplements, cosmetics, and over-the-counter (OTC) products that are being used as dietary supplements.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for microbiome therapeutics, diagnostics and FMTs, over the next decade. The research, analyses and insights presented in this report are based on revenue generation trends based on the sales of approved / late stage (estimated) microbiome therapeutics, diagnostic products and FMTs. The report also features the likely distribution of the current and forecasted opportunity within microbiome therapeutics market across [A] type of therapy (prescription drugs, prebiotics, and probiotics), [B] type of molecule (small molecules and biologics), [C] target indication (acne vulgaris, atopic dermatitis, CDI, Crohn’s disease, diabetes, irritable bowel syndrome, lactose intolerance, nonalcoholic steatohepatitis (NASH), ulcerative colitis, and 5+ categories), [D] therapeutic area (autoimmune disorders, dental disorders, digestive and gastrointestinal disorders, dermatological disorders, infectious diseases, metabolic disorders, oncology, and others), [E] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies), [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world), [G] leading drug developers, and [H] leading therapeutic products. In addition, it also features the likely distribution of the current and forecasted opportunity within microbiome diagnostics market across [A] target indication (Crohn’s disease, colorectal cancer, diabetes, irritable bowel syndrome, lung cancer, NASH, obesity, and ulcerative colitis), [B] therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and oncology), [C] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies), and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). In order to account for the uncertainties associated with the growth of microbiome market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company / organization names):

Lee Jones (President and Chief Executive Officer, Rebiotix)
Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic)
Colleen Cutcliffe (Co-founder and Chief Executive Officer, Whole Biome)
Nikole E Kimes (Co-founder and Vice President, Siolta Therapeutics)
James Burges (Executive Director, OpenBiome)
JP Benya (Vice President, Business Development, Assembly Biosciences)
Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories)
Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics)
Mark Heiman (Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics)
Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies)
Assaf Oron (Chief Business Officer, BiomX)
Pierre-Alain Bandinelli (Chief Business Officer, Da Volterra)
Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical)
Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state and likely evolution of microbiome therapeutics, diagnostics and FMT therapies market in the short-mid term and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to the human microbiome, including a discussion on the role of resident microorganisms in disease development (particularly for conditions caused by an imbalance in the microbiome) and in certain cases, prevention. It presents an elaborate discussion on various functions of the microbiota, emphasizing on the key aspects of the Human Microbiome Project (HMP). Further, the chapter describes the various types of microbiome therapeutics, such as probiotics and prebiotic drugs, which are available / under development. It also provides an overview of the regulatory requirements for live biotherapeutic products (LBPs), in addition to highlighting the challenges associated with the development of microbiome therapeutics.

Chapter 4 includes information on 260 microbiome therapeutics that are currently being evaluated in different stages of development (both clinical and preclinical / discovery). It features a comprehensive analysis of pipeline molecules based on their phases of development (clinical, preclinical, and discovery stage), type of molecule (small molecule and biologic), type of therapy (prebiotic, probiotic, and prescription drug), target indication(s), key therapeutic area(s), molecular / biological target (if available), mechanism of action (if available), route of administration, type of drug formulation (tablet, capsule, gel, lotion, cream, ointment, nasal spray and 4+ categories), dosing frequency (reported for clinical candidates only), and information on special drug designation (if any). Further, the chapter provides information on drug developer(s), highlighting their year of establishment, location of headquarters and company size. It also highlights the various microbiome therapeutics that have been discontinued over the last few years. In addition, the chapter highlights the various technology platforms that are being actively used for the development of microbiome therapeutics.

Chapter 5 features detailed profiles of key players (established after 2005) that are engaged in the development of three or more microbiome therapeutics in both preclinical and clinical stages of development, with at least one candidate in the late stages of development (phase II and above). Each profile features a brief overview of the company, its financial information (if available), microbiome-based product portfolio, information on advanced stage (phase II and above) pipeline candidates (featuring a drug overview, current status of development, clinical trial information, and clinical trial end-point analysis) and an informed future outlook.

Chapter 6 features a discussion on the various types of diagnostic tests, specifically highlighting the importance of next-generation sequencing within this field of research. Further, it includes information on over 30 microbiome diagnostic tests that are currently available / under development, along with information on the developer(s) (such as year of establishment, location of headquarters and company size), stage of development (commercialized and under development), type of sample used (blood, feces, saliva and vaginal swab), target indication(s), key therapeutic area(s), result turnaround time, and purpose of diagnosis. It also includes brief profiles of the popular diagnostic developers that are engaged in the development of four or more diagnostic tests. Additionally, it includes an indicative list of screening and profiling test kits, including information on the developer(s) (such as year of establishment, location of headquarters and company size), type of sample used (blood, feces, saliva and vaginal swab), key therapeutic area(s), and result turnaround time.

Chapter 7 presents an elaborate discussion on the historical evolution and other relevant aspects of FMT therapies, including details on the process of donor selection, procedure, route of administration, clinical guidelines, regulatory guidelines and insurance coverage. Further, it highlights the present scenario of FMT therapies, along with [A] a detailed assessment of the current market landscape of FMT therapies, providing information on industry developer(s) (such as year of establishment, location of headquarters and company size), status of development (commercialized, clinical, and preclinical stage), target indication(s), key therapeutic area(s), and route of administration, [B] a geographical clinical trial analysis of ongoing / planned / completed studies of FMTs sponsored by non-industry players, featuring details related to specific FMT therapies and analysis based on relevant parameters, such as the number of registered trials, year of registration, current status, phase of development, study design, type of sponsor(s), target indication(s), key therapeutic area(s), key focus areas, number of patients enrolled and leading non-industry player(s), and [C] information on the various stool banks (including year of establishment and location of headquarters), along with brief profiles of the most prominent stool banks located across the globe.

Chapter 8 features an insightful analysis of top indications, across various therapeutic areas under investigation, based on the 9-box AC matrix framework. It further includes a discussion on the relative market attractiveness and existing competition across the most popular disease indication(s). The purpose of the analysis is to enable companies to analyze their product portfolio, develop informed growth strategies (with regard to indications), and also make decisions related to developing products for the top indications.

Chapter 9 highlights the efforts of the top 11 big pharma players engaged in the field of microbiome therapeutics and diagnostics. It features a [A] heat map representation that highlights microbiome therapeutics under development (in partnership with core microbiome product developers), along with information on funding, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)), and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.

Chapter 10 presents the detailed analysis of start-ups / small-sized players (established in the last seven years, with less than 50 employees) engaged in the development of microbiome therapeutics and diagnostics. It includes a heat map analysis based on parameters, such as number of microbiome therapeutics under development, diversity of product portfolio, funding information (including funding amount, number of investors and evolution of investment activity), partnership activity, disease indication(s) being treated and focus therapeutic area(s), and strength of intellectual property portfolio.

Chapter 11 presents an elaborate discussion on the most commonly targeted therapeutic indications and brief descriptions of the microbiome-based drugs that are being developed against them. It highlights the key epidemiological facts about the specific diseases, available methods of diagnosis, and currently available treatment options and their side effects.

Chapter 12 presents details on various investments received by start-ups / small-sized companies (established in the last seven years, with less than 50 employees) that are focused on developing microbiome therapeutics and diagnostics. It also includes an analysis of the funding instances that have taken place in the market, up to 2019 (till October), highlighting the growing interest of the venture capital (VC) community and other strategic investors within this domain.
Chapter 13 feature an elaborate discussion on the various steps involved in the development and manufacturing of microbiome therapeutics. Further, the chapter includes [A] an indicative list of contract manufacturers, along with details on year of establishment, location of headquarters, company size, scale of operation, facility location and microbiome production capacity, [B] an indicative list of companies with in-house manufacturing facilities for microbiome therapeutics, along with details on their year of establishment, location of headquarters, company size, and [C] an indicative list of CROs that currently claim to have the necessary capabilities to offer various research services (such as screening, sequencing, characterization, analytical), along with details on year of establishment, location of headquarters, company size, and service portfolio details. Additionally, it includes an insightful Harvey ball analysis of key considerations that need to be assessed by industry stakeholders while selecting a suitable CMO / CRO partner.

Chapter 14 presents an assessment of the emerging role of big data, highlighting the development and implementation of various algorithms / tools to analyze data generated from microbiome research, in order to understand the relationship between the microbiome and the host. Further, it features [A] an insightful google trends analysis to demonstrate the rising interest of stakeholders in using big data tools to support microbiome research over the past decade, [B] a list of companies offering big data-related services / tools to support microbiome research, and [C] brief profiles of some of the popular companies that are engaged in this field of research.

Chapter 15 features an elaborate market forecast analysis, highlighting the future potential of microbiome therapeutics till 2030. Based on an informed top-down approach, taking into account current and projected performance of the microbiome therapeutics market, it features the likely distribution of the current and forecasted opportunity across [A] type of therapy (prescription drugs, prebiotics, and probiotics), [B] type of molecule (small molecules and biologics), [C] target indication (acne vulgaris, atopic dermatitis, CDI, Crohn’s disease, diabetes, irritable bowel syndrome, lactose intolerance, NASH, ulcerative colitis, and 5+ categories), [D] therapeutic area (autoimmune disorders, dental disorders, digestive and gastrointestinal disorders, dermatological disorders, infectious diseases, metabolic disorders, oncology, and others), [E] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies), [F] key geographical regions (North America, Europe, Asia-Pacific and rest of the world), [G] leading drug developers, and [H] leading therapeutic products. The potential sales forecast of the therapeutic products that are in late stages of development (phase III and above) is based on multiple relevant parameters, such as target consumer segments, region-specific disease prevalence, anticipated adoption of the late stage drugs and likely selling price.

Chapter 16 features a detailed market forecast analysis, highlighting the future potential of microbiome-based diagnostic tests till 2030. Based on multiple parameters, such as target consumer segments, disease prevalence, anticipated adoption of diagnostic tests and price, the analysis provides an informed opinion on the likely distribution of the current and forecasted opportunity across [A] target indication (Crohn’s disease, colorectal cancer, diabetes, irritable bowel syndrome, lung cancer, NASH, obesity, and ulcerative colitis), [B] therapeutic area (digestive and gastrointestinal disorders, metabolic disorders and oncology), [C] supply channel (hospital pharmacies, retail pharmacies, and online pharmacies), and [D] key geographical regions (North America, Europe, Asia-Pacific and rest of the world). It is worth mentioning that a bottom-up approach was adopted for this analysis, wherein our estimates of the likely size of the microbiome-based diagnostics market were validated using relevant datapoints and inputs from primary research. The chapter features market projections both in terms of value (USD million) and volume (number of diagnostic tests).

Chapter 17 features an informed market forecast analysis, highlighting the future opportunity within the FMT therapies market till 2030, based on parameters, such as the average number of FMT procedures conducted in a year and average cost of approved FMT therapies. It is worth mentioning that the chapter features market projections both in terms of value (USD million) and volume (number of procedures).

Chapter 18 is a case study focused on the other applications of microbiome products, such as in the field of agriculture, animal health, plant health, and food products. It also features a list of nearly 80 microbiome products, including probiotic supplements, medical food products, cosmetics, and OTC products, which are being used as dietary supplements.

Chapter 19 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 20 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Lee Jones (President and Chief Executive Officer, Rebiotix), Veronika Oudova (Co-founder and Chief Executive Officer, S-Biomedic), Colleen Cutcliffe (Co-founder and Chief Executive Officer, Whole Biome), Nikole E Kimes (Co-founder and Vice President, Siolta Therapeutics), James Burges (Executive Director, OpenBiome), JP Benya (Vice President, Business Development, Assembly Biosciences), Debbie Pinkston (Vice President, Sales and Business Development, List Biological Laboratories), Gregory J Kuehn (Vice President, Business Development and Marketing, Metabiomics), Mark Heiman (Chief Scientific Officer and Vice President, Research, MicroBiome Therapeutics), Alexander Segal (Vice President, Business Development, Universal Stabilization Technologies), Assaf Oron (Chief Business Officer, BiomX), Pierre-Alain Bandinelli (Chief Business Officer, Da Volterra), Alexander Lin (Associate General Manager, Chung Mei Pharmaceutical), and Aaron Wright (Senior Scientist, Pacific Northwest National Laboratories)

Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report.

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of Microbiota and Microbiome
3.2.1. Discovery of the Human Microbiome
3.2.2. Functions of the Human Microbiome

3.3. Overview of Gut Flora
3.3.1. Role of Gut Flora in Healthy Individuals
3.3.2. Factors Affecting Gut Flora
3.3.2.1. Antibiotic Consumption
3.3.2.2. Age and Pregnancy
3.3.2.2.1. Mode of Childbirth
3.3.2.2.2. Type of Feeding
3.3.2.2.3. Antibiotic Consumption by Mother
3.3.2.3. Stress-related Factors
3.3.2.4. Dietary Factors
3.3.2.5. Impact of Lifestyle

3.4. The Microbiome and Disease
3.4.1. Cancer
3.4.2. Inflammatory Bowel Disease (IBD)
3.4.3. Obesity
3.4.4. Parkinson’s Disease
3.4.5. Type-II Diabetes
3.4.6. Other Disease Indications
3.5. Impact of Microbiota on Drug Pharmacokinetics
3.6. Impact of Microbiota on Therapeutic Outcomes

3.7. Microbiome Therapeutics
3.7.1. Probiotics
3.7.1.1. Beneficial Bacterial Strains
3.7.1.1.1. Lactobacilli
3.7.1.1.2. Bifidobacteria
3.7.1.1.3. Others

3.7.1.2. Key Therapeutic Areas
3.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
3.7.1.2.2. Bacterial Vaginosis
3.7.1.2.3. High Blood Pressure
3.7.1.2.4. Hypercholesterolemia
3.7.1.2.5. Infectious Childhood Diarrhea (ICD)
3.7.1.2.6. Inflammatory Bowel Disease (IBD)
3.7.1.2.7. Lactose Intolerance
3.7.1.2.8. Vitamin Production
3.7.1.2.9. Weight Management

3.7.1.3. Side Effects of Probiotics

3.7.2. Prebiotics
3.7.2.1. Sources of Prebiotics
3.7.2.2. Types of Prebiotics
3.7.2.2.1. Fructo-Oligosaccharides (FOS)
3.7.2.2.2. Galacto-Oligosaccharides (GOS)
3.7.2.2.3. Inulin

3.7.2.3. Key Therapeutic Areas
3.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
3.7.2.3.2. Constipation
3.7.2.3.3. Gastrointestinal Disorders
3.7.2.3.4. Dysbiosis
3.7.2.4. Side Effects of Prebiotics

3.8. The Human Microbiome Project (HMP)
3.8.1. Project Approach
3.8.2. Project Initiatives
3.8.3. Project Achievements

3.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
3.10. Key Challenges in the Development of Microbiome Therapeutics
3.11. Future Perspectives

4. MICROBIOME THERAPEUTICS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Microbiome Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Molecule
4.2.3. Analysis by Type of Therapy
4.2.4. Analysis by Target Indication
4.2.5. Analysis by Therapeutic Area
4.2.6. Analysis by Dosing Frequency
4.2.7. Analysis by Route of Administration
4.2.8. Analysis by Drug Formulation

4.3. Microbiome Therapeutics: Early-Stage Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Type of Molecule
4.3.3. Analysis by Type of Therapy
4.3.4. Analysis by Target Indication
4.3.5. Analysis by Therapeutic Area

4.4. Microbiome Therapeutics: List of Drug Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Location of Headquarters
4.4.3. Analysis by Company Size
4.4.4. Analysis by Company Size and Location of Headquarters
4.4.5. Leading Drug Developers: Analysis by Number of Microbiome Therapeutics

4.5. Microbiome Therapeutics: List of Discontinued Drugs
4.6. Emerging Role of Microbiome in Gut-Brain Axis
4.7. Microbiome Therapeutics: List of Technology Platforms

5. COMPANY AND DRUG PROFILES
5.1. Chapter Overview
5.2. 4D Pharma
5.2.1. Company Overview
5.2.2. Microbiome-based Product Portfolio
5.2.2.1. Blautix®
5.2.2.1.1. Drug Overview
5.2.2.1.2. Current Status of Development
5.2.2.1.3. Clinical Studies
5.2.2.1.4. Clinical Trial End-Point Analysis
5.2.3. Recent Developments and Future Outlook

5.3. Armata Pharmaceuticals
5.3.1. Company Overview
5.3.2. Microbiome-Based Product Portfolio
5.3.2.1. C16G2
5.3.2.1.1. Drug Overview
5.3.2.1.2. Current Status of Development
5.3.2.1.3. Clinical Studies
5.3.2.1.4. Clinical Trial End-Point Analysis
5.3.3. Recent Developments and Future Outlook

5.4. Evelo Biosciences
5.4.1. Company Overview
5.4.2. Microbiome-Based Product Portfolio
5.4.2.1. EDP1503
5.4.2.1.1. Drug Overview
5.4.2.1.2. Current Status of Development
5.4.2.1.3. Clinical Studies
5.4.2.1.4. Clinical Trial End-Point Analysis
5.4.3. Recent Developments and Future Outlook

5.5. Rebiotix (Acquired by Ferring Pharmaceuticals)
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Microbiome-Based Product Portfolio
5.5.3.1. RBX2660
5.5.3.1.1. Drug Overview
5.5.3.1.2. Current Status of Development
5.5.3.1.3. Clinical Studies
5.5.3.1.4. Clinical Trial End-Point Analysis
5.5.4. Recent Developments and Future Outlook

5.6. Seres Therapeutics
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Microbiome-Based Product Portfolio
5.6.3.1. SER-109
5.6.3.1.1. Drug Overview
5.6.3.1.2. Current Status of Development
5.6.3.1.3. Clinical Studies
5.6.3.1.4. Clinical Trial End-Point Analysis

5.6.3.2. SER-287
5.6.3.2.1. Current Status of Development
5.6.3.2.3. Clinical Studies
5.6.3.2.4. Clinical Trial End-Point Analysis
5.6.4. Recent Developments and Future Outlook

5.7. Vedanta Biosciences
5.7.1. Company Overview
5.7.2. Microbiome-Based Product Portfolio
5.7.2.1. VE303
5.7.2.1.1. Drug Overview
5.7.2.1.2. Current Status of Development
5.7.2.1.3. Clinical Studies
5.7.3.1.4. Clinical Trial End-Point Analysis
5.7.3. Recent Developments and Future Outlook

6. MICROBIOME DIAGNOSTICS: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Overview of Microbiome Diagnostic Tests
6.3. Microbiome Diagnostic Tests: Marketed and Under Development Products
6.3.1. Analysis by Stage of Development
6.3.2. Analysis by Type of Sample Required
6.3.3. Analysis by Target Indication
6.3.4. Analysis by Therapeutic Area

6.4. Microbiome Diagnostic Tests: List of Diagnostic Developers
6.4.1. Analysis by Year of Establishment
6.4.2. Analysis by Location of Headquarters
6.4.3. Analysis by Company Size
6.4.4. Analysis by Company Size and Location of Headquarters
6.4.5. Leading Diagnostic Developers: Analysis by Number of Microbiome Diagnostics

6.5. Profiles of Prominent Diagnostic Developers
6.5.1. Enterome Bioscience
6.5.1.1. Company Overview
6.5.1.2. Service Portfolio

6.5.2. Vaiomer
6.5.2.1. Company Overview
6.5.2.2. Service Portfolio
6.6. Overview of Microbiome Screening / Profiling Tests
6.6.1. List of Microbiome Screening / Profiling Tests
6.6.2. List of Microbiome Screening / Profiling Test Developers

7. FECAL MICROBIOTA THERAPY (FMT)
7.1. Chapter Overview
7.2. Introduction to FMT
7.3. Historical Overview
7.4. FMT: Procedure and Clinical Relevance
7.4.1. Donor Selection
7.4.2. Administration Procedure
7.4.3. Routes of Administration
7.4.4. Consequences and Adverse Events
7.4.5. Clinical Guidelines Associated with FMT

7.5. Regulatory Guidelines Related to FMT
7.6. Insurance Coverage for FMT

7.7. FMT: Competitive Landscape
7.7.1. Marketed / Development Pipeline (Industry Players)
7.7.1.1. Analysis by Phase of Development
7.7.1.2. Analysis by Therapeutic Area
7.7.1.3. Analysis by Route of Administration

7.7.2. List of Developers (Industry Players)
7.7.2.1. Analysis by Year of Establishment
7.7.2.2. Analysis by Location of Headquarters
7.7.2.3. Analysis by Company Size

7.8. Clinical Trial Analysis (Non-Industry Sponsored)
7.8.1. Scope and Methodology
7.8.2. List of Clinical Trials
7.8.2.1. Analysis by Trial Registration Year
7.8.2.2. Analysis by Trial Status
7.8.2.3. Analysis by Phase of Development
7.8.2.4. Analysis by Patients Enrolled
7.8.2.5. Analysis of Number of Patients Enrolled by Trial Registration Year
7.8.2.6. Analysis by Therapeutic Area
7.8.2.7. Analysis by Popular Target Indications
7.8.2.8. Analysis by Trial Registration Year and Recruitment Status
7.8.2.9. Analysis by Study Design
7.8.2.10. Leading Non-Industry Players: Analysis by Number of Trials
7.8.2.11. Geographical Analysis by Number of Clinical Trials
7.8.2.12. Geographical Analysis by Enrolled Patient Population
7.8.2.13. Analysis by Type of Sponsor / Collaborator
7.8.2.14. Analysis by Trial Focus
7.8.2.15. Key Clinical Trials

7.9. Stool Banks
7.9.1. Introduction to Stool Banks
7.9.2. List of Stool Banks

7.9.3. Profiles of Prominent Stool Banks
7.9.3.1. AdvancingBio
7.9.3.1.1. Overview
7.9.3.1.2. Fecal Microbiota Preparation

7.9.3.2. Asia Microbiota bank
7.9.3.2.1. Overview
7.9.3.2.2. Fecal Microbiota Preparation

7.9.3.3. Enterobiotix
7.9.3.3.1. Overview
7.9.3.3.2. Fecal Microbiota Preparation

7.9.3.4. Flora Medicine
7.9.3.4.1. Overview
7.9.3.4.2. Fecal Microbiota Preparation

7.9.3.5. OpenBiome
7.9.3.5.1. Overview
7.9.3.5.2. Fecal Microbiota Preparation

8. ATTRACTIVENESS COMPETITIVENESS (AC) MATRIX
8.1. Chapter Overview
8.2. AC Matrix: An Overview
8.2.1. Strong Opportunity Areas
8.2.2. Average Opportunity Areas
8.2.3. Weak Opportunity Areas

8.3. AC Matrix: Analytical Methodology
8.4. AC Matrix: Plotting the Information
8.5. AC Matrix: Analyzing the Data
8.5.1. Strong Opportunity Areas
8.5.2. Average Opportunity Areas
8.5.3. Weak Opportunity Areas

8.6. Concluding Remarks

9. MICROBIOME RELATED INITIATIVES OF BIG PHARMACEUTICAL PLAYERS
9.1. Chapter Overview
9.2. Scope and Methodology

9.3. Initiatives of Big Pharmaceutical Players
9.3.1. Analysis by Portfolio Diversity
9.3.2. Analysis by Phase of Development
9.3.3. Analysis by Type of Molecule
9.3.4. Analysis by Type of Therapy
9.3.5. Analysis by Diversity of Therapeutic Areas

9.4. Benchmark Analysis of Big Pharmaceutical Players
9.4.1. Spider Web Analysis: Company A
9.4.2. Spider Web Analysis: Company B
9.4.3. Spider Web Analysis: Company C
9.4.4. Spider Web Analysis: Company D
9.4.5. Spider Web Analysis: Company E
9.4.6. Spider Web Analysis: Company F
9.4.7. Spider Web Analysis: Company G
9.4.8. Spider Web Analysis: Company H
9.4.9. Spider Web Analysis: Company I
9.4.10. Spider Web Analysis: Company J
9.4.11. Spider Web Analysis: Company K

10. START-UP HEALTH INDEXING
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Benchmark Analysis of Start-ups
10.3.1. Benchmark Analysis by Portfolio Diversity
10.3.2. Benchmark Analysis by Phase of Development
10.3.3. Benchmark Analysis by Diversity in Therapeutic Areas
10.3.4. Benchmark Analysis by Funding Amount
10.3.5. Benchmark Analysis by Number of Investors
10.3.6. Benchmark Analysis by Progression in Funding
10.3.7. Benchmark Analysis by Partnership Activity
10.3.8. Benchmark Analysis by Patent Portfolio
10.3.9. Start-up Health Indexing: Roots Analysis Perspective

11. KEY THERAPEUTIC AREAS
11.1. Chapter Overview
11.2. Metabolic Disorders
11.2.1. Diabetes
11.2.1.1. Disease Description
11.2.1.2. Associated Health Risks / Complications
11.2.1.3. Epidemiology
11.2.1.4. Disease Diagnosis
11.2.1.5. Current Treatment Options
11.2.1.5.1. Insulin Therapies
11.2.1.5.2. Non-Insulin Therapies
11.2.1.6. Side Effects of Current Treatment Options
11.2.1.7. Microbiome Therapeutics for Diabetes

11.2.2. Lactose Intolerance
11.2.2.1. Disease Description
11.2.2.2. Epidemiology
11.2.2.3. Current Treatment Options
11.2.2.4. Microbiome Therapeutics for Lactose Intolerance

11.2.3. Nonalcoholic Steatohepatitis (NASH)
11.2.3.1. Disease Description
11.2.3.2. Epidemiology
11.2.3.3. Current Treatment Options
11.2.3.4. Microbiome Therapeutics for NASH

11.2.4. Primary Hyperoxaluria
11.2.4.1. Disease Description
11.2.4.2. Epidemiology
11.2.4.3. Current Treatment Options
11.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria

11.2.5. Obesity
11.2.5.1. Disease Description
11.2.5.2. Epidemiology
11.2.5.3. Current Treatment Options
11.2.5.4. Side Effects of Current Treatment Options
11.2.5.5. Microbiome Therapeutics for Obesity

11.3. Digestive and Gastrointestinal Disorders
11.3.1. Crohn’s Disease
11.3.1.1. Disease Description
11.3.1.2. Epidemiology
11.3.1.3. Current Treatment Options
11.3.1.4. Side Effects of Current Treatment Options
11.3.1.5. Microbiome Therapeutics for Crohn’s Disease

11.3.2. Irritable Bowel Syndrome (IBS)
11.3.2.1. Disease Description
11.3.2.2. Epidemiology
11.3.2.3. Current Treatment Options
11.3.2.4. Microbiome Therapeutics for IBS

11.3.3. Ulcerative Colitis
11.3.3.1. Disease Description
11.3.3.2. Epidemiology
11.3.3.3. Current Treatment Options
11.3.3.4. Side Effects of Current Treatment Options
11.3.3.5. Microbiome Therapeutics for Ulcerative Colitis

11.4. Oncological Indications
11.4.1. Colorectal Cancer
11.4.1.1. Disease Description
11.4.1.2. Epidemiology
11.4.1.3. Current Treatment Options
11.4.1.4. Side Effects of Current Treatments
11.4.1.5. Microbiome Therapeutics for Colorectal Cancer

11.4.2. Lung Cancer
11.4.2.1. Disease Description
11.4.2.2. Epidemiology
11.4.2.3. Current Treatment Options
11.4.2.4. Side Effects of Current Treatment Options
11.4.2.5. Microbiome Therapeutics for Lung Cancer

11.5. Dermatological Disorders
11.5.1. Acne Vulgaris
11.5.1.1. Disease Description
11.5.1.2. Epidemiology
11.5.1.3. Current Treatment Options
11.5.1.4. Side Effects of Current Treatment Options
11.5.1.5. Microbiome Therapeutics for Acne Vulgaris

11.6. Infectious Diseases
11.6.1. Clostridium Difficile Infections (CDIs)
11.6.1.1. Disease Description
11.6.1.2. Epidemiology
11.6.1.3. Disease Diagnosis
11.6.1.4. Current Treatment Options
11.6.1.5. Side Effects of Current Treatment Options
11.6.1.6. Microbiome Therapeutics for CDI

11.6.2. Bacterial Vaginosis
11.6.2.1. Disease Description
11.6.2.2. Epidemiology
11.6.2.3. Current Treatment Options
11.6.2.4. Side Effects of Current Treatment Options
11.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding

12.3. Microbiome Therapeutics and Diagnostics: List of Funding and Investments
12.3.1. Analysis by Number of Instances
12.3.2. Analysis by Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Type of Company
12.3.5. Analysis by Purpose of Funding
12.3.6. Analysis by Type of Molecule
12.3.7. Analysis by Target Indication
12.3.8. Analysis by Therapeutic Area
12.3.9. Analysis by Geography
12.3.10. Most Active Players
12.3.11. Most Active Investors
12.3.12. Analysis by Type of Investors
12.3.13. Analysis by Location of Investors
12.4. Concluding Remarks

13. CONTRACT SERVICES FOR MICROBIOME THERAPEUTICS
13.1. Chapter Overview
13.2. Manufacturing Microbiome Therapeutics
13.2.1. Key Steps Involved
13.2.2. Associated Challenges
13.2.3. Growing Demand for Contract Manufacturing Services

13.2.4. Contract Manufacturing Organizations (CMOs)
13.2.4.1. Introduction to Contract Manufacturing
13.2.4.2. List of Organizations Offering Services for Microbiome Therapeutics

13.2.5. In-House Manufacturers
13.2.5.1. Introduction to In-House Manufacturing
13.2.5.2. List of In-House Manufacturers

13.3. Microbiome Therapeutics-related R&D
13.3.1. Growing Demand for Contract Research Services
13.3.2. Contract Research Organizations (CROs)
13.3.2.1. Introduction to Contract Research
13.3.2.2. List of Organizations Offering Services for Microbiome Therapeutics

13.4. Key Considerations for Selecting a Suitable CMO / CRO Partner

14. BIG DATA AND MICROBIOME THERAPEUTICS
14.1. Chapter Overview
14.2. Introduction to Big Data
14.3. Internet of Things
14.4. Growing Interest in Big Data: Google Trends Analysis
14.5. Key Application Areas

14.6. Big Data in Microbiome Research
14.6.1. Microbiome Data and Personalized Medicine
14.6.2. Microbiome-related Data Management Challenges
14.6.3. National Microbiome Data Center

14.7. Big Data Services for Microbiome Research: List of Companies
14.8. Big Data Services for Microbiome Research: Profiles of Key Players
14.8.1. Human Longevity
14.8.1.1. Company Overview
14.8.1.2. Technology and Service Portfolio
14.8.1.3. Recent Developments

14.8.2. Resilient Biotics
14.8.2.1. Company Overview
14.8.2.2. Technology and Service Portfolio
14.8.2.3. Recent Developments

14.8.3. Resphera Biosciences
14.8.3.1. Company Overview
14.8.3.2. Technology and Service Portfolio

15. MICROBIOME THERAPEUTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Forecast Methodology

15.4. Overall Microbiome Therapeutics Market, 2019-2030
15.4.1. Microbiome Therapeutics Market: Distribution by Type of Therapy, 2019-2030
15.4.1.1. Microbiome Therapeutics Market for Prescription Drugs, 2019-2030
15.4.1.2. Microbiome Therapeutics Market for Prebiotic Drugs, 2019-2030
15.4.1.3. Microbiome Therapeutics Market for Probiotic Drugs, 2019-2030

15.4.2. Microbiome Therapeutics Market: Distribution by Type of Molecule, 2019-2030
15.4.2.1. Microbiome Therapeutics Market for Small Molecules, 2019-2030
15.4.2.2. Microbiome Therapeutics Market for Biologics, 2019-2030

15.4.3. Microbiome Therapeutics Market: Distribution by Target Indication, 2019-2030
15.4.3.1. Microbiome Therapeutics Market for Acne Vulgaris, 2019-2030
15.4.3.2. Microbiome Therapeutics Market for Atopic Dermatitis, 2019-2030
15.4.3.3. Microbiome Therapeutics Market for CDI, 2019-2030
15.4.3.4. Microbiome Therapeutics Market for Colorectal Cancer, 2019-2030
15.4.3.5. Microbiome Therapeutics Market for Crohn’s Disease, 2019-2030
15.4.3.6. Microbiome Therapeutics Market for Dental Caries, 2019-2030
15.4.3.7. Microbiome Therapeutics Market for Diabetes, 2019-2030
15.4.3.8. Microbiome Therapeutics Market for IBS, 2019-2030
15.4.3.9. Microbiome Therapeutics Market for Lactose Intolerance, 2019-2030
15.4.3.10. Microbiome Therapeutics Market for Lung Cancer, 2019-2030
15.4.3.11. Microbiome Therapeutics Market for NASH, 2019-2030
15.4.3.12. Microbiome Therapeutics Market for Primary Hyperoxaluria, 2019-2030
15.4.3.13. Microbiome Therapeutics Market for Psoriasis, 2019-2030
15.4.3.14. Microbiome Therapeutics Market for Ulcerative Colitis, 2019-2030
15.4.3.15. Microbiome Therapeutics Market for Others, 2019-2030

15.4.4. Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2019-2030
15.4.4.1. Microbiome Therapeutics Market for Autoimmune Disorders, 2019-2030
15.4.4.2. Microbiome Therapeutics Market for Dental Disorders, 2019-2030
15.4.4.3. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2019-2030
15.4.4.4. Microbiome Therapeutics Market for Dermatological Disorders, 2019-2030
15.4.4.5. Microbiome Therapeutics Market for Infectious Diseases, 2019-2030
15.4.4.6. Microbiome Therapeutics Market for Metabolic Disorders, 2019-2030
15.4.4.7. Microbiome Therapeutics Market for Oncology, 2019-2030
15.4.4.8. Microbiome Therapeutics Market for Others, 2019-2030

15.4.5. Microbiome Therapeutics Market: Distribution by Supply Channel, 2019-2030
15.4.5.1. Microbiome Therapeutics Market for Hospital Pharmacies, 2019-2030
15.4.5.2. Microbiome Therapeutics Market for Retail Pharmacies, 2019-2030
15.4.5.3. Microbiome Therapeutics Market for Online Pharmacies, 2019-2030

15.4.6. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2019-2030
15.4.6.1. Microbiome Therapeutics Market in North America, 2019-2030
15.4.6.2. Microbiome Therapeutics Market in Europe, 2019-2030
15.4.6.3. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2019-2030

15.4.7. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2019-2030
15.5. Microbiome Therapeutics Market: Distribution by Leading Therapeutic Products, 2019-2030
15.5.1. Drug-wise Sales Forecast
15.5.1.1. IBP-9414 (Infant Bacterial Therapeutics)
15.5.1.2. Sales Forecast (USD Million)
15.5.1.3. Net Present Value (USD Million)
15.5.1.4. Value Creation Analysis

15.5.2.1. Oxabact (OxThera)
15.5.2.2. Sales Forecast (USD Million)
15.5.2.3. Net Present Value (USD Million)
15.5.2.4. Value Creation Analysis

15.5.3.1. RBX2660 (Rebiotix)
15.5.3.2. Sales Forecast (USD Million)
15.5.3.3. Net Present Value (USD Million)
15.5.3.4. Value Creation Analysis

15.5.4.1. RP-G28 (Ritter Pharmaceuticals)
15.5.4.2. Sales Forecast (USD Million)
15.5.4.3. Net Present Value (USD Million)
15.5.4.4. Value Creation Analysis

15.5.5.1. SER-109 (Seres Therapeutics)
15.5.5.2. Sales Forecast (USD Million)
15.5.5.3. Net Present Value (USD Million)
15.5.5.4. Value Creation Analysis

16. MICROBIOME DIAGNOSTICS: MARKET FORECAST AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Scope and Limitations
16.3 Forecast Methodology
16.4. Overall Microbiome Diagnostics Market, 2019-2030
16.4.1. Overall Microbiome Diagnostics Market, 2019-2030 (By Value)
16.4.2. Overall Microbiome Diagnostics Market, 2019-2030 (By Volume)

16.5. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-2030
16.5.1. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-2030 (By Value)
16.5.1.1. Microbiome Diagnostics Market for Crohn’s Disease, 2019-2030 (By Value)
16.5.1.2. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (By Value)
16.5.1.3. Microbiome Diagnostics Market for Diabetes, 2019-2030 (By Value)
16.5.1.4. Microbiome Diagnostics Market for IBS, 2019-2030 (By Value)
16.5.1.5. Microbiome Diagnostics Market for Lung Cancer, 2019-2030 (By Value)
16.5.1.6. Microbiome Diagnostics Market for NASH, 2019-2030 (By Value)
16.5.1.7. Microbiome Diagnostics Market for Obesity, 2019-2030 (By Value)
16.5.1.8. Microbiome Diagnostics Market for Ulcerative Colitis, 2019-2030 (By Value)

16.5.2. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-2030 (By Volume)
16.5.2.1. Microbiome Diagnostics Market for Crohn’s Disease, 2019-2030 (By Volume)
16.5.2.2. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (By Volume)
16.5.2.3. Microbiome Diagnostics Market for Diabetes, 2019-2030 (By Volume)
16.5.2.4. Microbiome Diagnostics Market for IBS, 2019-2030 (By Volume)
16.5.2.5. Microbiome Diagnostics Market for Lung Cancer, 2019-2030 (By Volume)
16.5.2.6. Microbiome Diagnostics Market for NASH, 2019-2030 (By Volume)
16.5.2.7. Microbiome Diagnostics Market for Obesity, 2019-2030 (By Volume)
16.5.2.8. Microbiome Diagnostics Market for Ulcerative Colitis, 2019-2030 (By Volume)

16.6. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030
16.6.1. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030 (By Value)
16.6.1.2. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (By Value)
16.6.1.2. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (By Value)
16.6.1.3. Microbiome Diagnostics Market for Oncology, 2019-2030 (By Value)

16.6.2. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030 (By Volume)
16.6.2.1. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (By Volume)
16.6.2.2. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (By Volume)
16.6.2.3. Microbiome Diagnostics Market for Oncology, 2019-2030 (By Volume)

16.7. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-2030
16.7.1. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-2030 (By Value)
16.7.1.1. Microbiome Diagnostics Market for Hospital Pharmacies, 2019-2030 (By Value)
16.7.1.2. Microbiome Diagnostics Market for Retail Pharmacies, 2019-2030 (By Value)
16.7.1.3. Microbiome Diagnostics Market for Online Pharmacies, 2019-2030 (By Value)

16.7.2. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-2030 (By Volume)
16.7.2.1. Microbiome Diagnostics Market for Hospital Pharmacies, 2019-2030 (By Volume)
16.7.2.2. Microbiome Diagnostics Market for Retail Pharmacies, 2019-2030 (By Volume)
16.7.2.3. Microbiome Diagnostics Market for Online Pharmacies, 2019-2030 (By Volume)

16.8. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030
16.8.1. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030 (By Value)
16.8.1.1. Microbiome Diagnostics Market in North America, 2019-2030 (By Value)
16.8.1.2. Microbiome Diagnostics Market in Europe, 2019-2030 (By Value)
16.8.1.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (By Value)

16.8.2. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030 (By Volume)
16.8.2.1. Microbiome Diagnostics Market in North America, 2019-2030 (By Volume)
16.8.2.2. Microbiome Diagnostics Market in Europe, 2019-2030 (By Volume)
16.8.2.3. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (By Volume)

17. FECAL MICROBIOTA THERAPIES: MARKET FORECAST AND OPPORTUNITY ANALYSIS
17.1. Chapter Overview
17.2. Scope and Limitations
17.3. Forecast Methodology
17.4. Overall FMT Market, 2019-2030
17.4.1. Overall FMT Market, 2019-2030 (By Value)
17.4.2. Overall FMT Market, 2019-2030 (By Volume)

17.5. Overall Microbiome Market by Product Offerings, 2019-2030

18. CASE STUDY: MICROBIOME-BASED PRODUCTS IN OTHER INDUSTRIES
18.1. Chapter Overview
18.2. List of Microbiome Products in Other Industries
18.2.1. Applications of Microbiome Based Products in Cosmetics and Food Industry
18.3. Applications of Microbiome Based Products in Agriculture Industry
18.4. Future Prospects

19. CONCLUDING REMARKS

20. EXECUTIVE INSIGHTS
20.1 Chapter Overview
20.2. Rebiotix
20.2.1. Company / Organization Snapshot
20.2.2. Interview Transcript: Lee Jones, President and Chief Executive Officer

20.3. S-Biomedic
20.3.1. Company / Organization Snapshot
20.3.2. Interview Transcript: Veronika Oudova, Co-founder and Chief Executive Officer

20.4. Whole Biome
20.4.1. Company / Organization Snapshot
20.4.2. Interview Transcript: Colleen Cutcliffe, Co-founder and Chief Executive Officer

20.5. Siolta Therapeutics
20.5.1. Company / Organization Snapshot
20.5.2. Interview Transcript: Nikole E Kimes, Co-founder and Vice President

20.6. OpenBiome
20.6.1. Company / Organization Snapshot
20.6.2. Interview Transcript: James Burges, Executive Director

20.7 Assembly Biosciences
20.7.1. Company / Organization Snapshot
20.7.2. Interview Transcript: JP Benya, Vice President, Business Development

20.8. List Biological Laboratories
20.8.1. Company / Organization Snapshot
20.8.2. Interview Transcript: Debbie Pinkston, Vice President, Sales and Business Development

20.9. Metabiomics
20.9.1. Company / Organization Snapshot
20.9.2. Interview Transcript: Gregory J Kuehn, Vice President, Business Development and Marketing

20.10. MicroBiome Therapeutics
20.10.1. Company / Organization Snapshot
20.10.2. Interview Transcript: Mark Heiman, Chief Scientific Officer and Vice President, Research

20.11. Universal Stabilization Technologies
20.11.1. Company / Organization Snapshot
20.11.2. Interview Transcript: Alexander Segal, Vice President, Business Development

20.12. BiomX
20.12.1. Company / Organization Snapshot
20.12.2. Interview Transcript: Assaf Oron, Chief Business Officer

20.13. Da Volterra
20.13.1. Company / Organization Snapshot
20.13.2. Interview Transcript: Pierre-Alain Bandinelli, Chief Business Officer

20.14. Chung Mei Pharmaceutical
20.14.1. Company / Organization Snapshot
20.14.2. Interview Transcript: Alexander Lin, Associate General Manager

20.15. Pacific Northwest National Laboratories
20.15.1. Company / Organization Snapshot
20.15.2. Interview Transcript: Aaron Wright, Senior Scientist

21. APPENDIX I: TABULATED DATA

22. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1. Benefits of the Human Microbiota
Figure 3.2. Factors Affecting Gut Flora
Figure 3.3. Factors Affecting Gut Microbiota in Infants
Figure 3.4. Impact of Diet on Gut Microbiota
Figure 3.5. Types of Microbiome Therapeutics
Figure 3.6. Approaches to Design Microbiome Therapeutics
Figure 3.7. Health Benefits of Probiotics
Figure 3.8. Mechanisms of Action of Probiotics
Figure 3.9. Beneficial Bacterial Strains for Probiotics
Figure 3.10. Key Achievements of the Human Microbiome Project (HMP)
Figure 3.11. Key Challenges in Developing Microbiome Therapeutics
Figure 4.1. Microbiome Therapeutics Clinical Pipeline: Distribution by Phase of Development
Figure 4.2. Microbiome Therapeutics Clinical Pipeline: Distribution by Type of Molecule
Figure 4.3. Microbiome Therapeutics Clinical Pipeline: Distribution by Type of Therapy
Figure 4.4. Microbiome Therapeutics Clinical Pipeline: Distribution by Target Indication
Figure 4.5. Microbiome Therapeutics Clinical Pipeline: Distribution by Therapeutic Area
Figure 4.6. Microbiome Therapeutics Clinical Pipeline: Distribution by Dosing Frequency
Figure 4.7. Microbiome Therapeutics Clinical Pipeline: Distribution by Route of Administration
Figure 4.8. Microbiome Therapeutics Clinical Pipeline: Distribution by Drug Formulation
Figure 4.9. Microbiome Therapeutics Preclinical Pipeline: Distribution by Phase of Development
Figure 4.10. Microbiome Therapeutics Preclinical Pipeline: Distribution by Type of Molecule
Figure 4.11. Microbiome Therapeutics Preclinical Pipeline: Distribution by Type of Therapy
Figure 4.12. Microbiome Therapeutics Preclinical Pipeline: Distribution by Target Indication
Figure 4.13. Microbiome Therapeutics Preclinical Pipeline: Distribution by Therapeutic Area
Figure 4.14. Microbiome Therapeutic Developers: Distribution by Year of Establishment
Figure 4.15. Microbiome Therapeutic Developers: Distribution by Location of Headquarters
Figure 4.16. Microbiome Therapeutic Developers: Distribution by Company Size
Figure 4.17. Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Figure 4.18. Microbiome Therapeutic Developers: Most Active Players
Figure 5.1. 4D Pharma: Microbiome-Based Product Portfolio
Figure 5.2. Blautix®: Clinical Trial Timeline and Patient Segment
Figure 5.3. Armata Pharmaceuticals: Microbiome-Based Product Portfolio
Figure 5.4. C16G2: Clinical Trial Timeline and Patient Segment
Figure 5.5. Evelo Biosciences: Microbiome-Based Product Portfolio
Figure 5.6. EDP1503: Clinical Trial Timeline and Patient Segment
Figure 5.7. Ferring Pharmaceuticals: Annual Revenues, 2014-2018 (DKK Million)
Figure 5.8. Rebiotix: Microbiome-Based Product Portfolio
Figure 5.9. RBX2660: Clinical Trial Timeline and Patient Segment
Figure 5.10. Seres Therapeutics: Annual Revenues, 2016-H1 2019 (USD Million)
Figure 5.11. Seres Therapeutics: Microbiome-Based Product Portfolio
Figure 5.12. SER-109: Clinical Trial Timeline and Patient Segment
Figure 5.13. SER-287: Clinical Trial Timeline and Patient Segment
Figure 5.14. Vedanta Biosciences: Microbiome-Based Product Portfolio
Figure 5.15. VER-303: Clinical Trial Timeline and Patient Segment
Figure 6.1. Key Steps in 16S rRNA Gene Sequence Analysis
Figure 6.2. Microbiome Diagnostics: Distribution by Stage of Development
Figure 6.3. Microbiome Diagnostics: Distribution by Type of Sample Required
Figure 6.4. Microbiome Diagnostics: Distribution by Target Indication
Figure 6.5. Microbiome Diagnostics: Distribution by Therapeutic Area
Figure 6.6. Microbiome Diagnostic Developers: Distribution by Year of Establishment
Figure 6.7. Microbiome Diagnostic Developers: Distribution by Location of Headquarters
Figure 6.8. Microbiome Diagnostic Developers: Distribution by Company Size
Figure 6.9. Microbiome Diagnostic Developers: Distribution by Company Size and Location of Headquarters
Figure 6.10. Microbiome Diagnostic Developers: Most Active Players
Figure 7.1. Working Mechanism of a Microflora Refinement System
Figure 7.2. FMT: Distribution by Phase of Development
Figure 7.3. FMT: Distribution by Therapeutic Area
Figure 7.4. FMT: Distribution by Route of Administration
Figure 7.5. FMT Developers: Distribution by Year of Establishment
Figure 7.6. FMT Developers: Distribution by Location of Headquarters
Figure 7.7. FMT Developers: Distribution by Company Size
Figure 7.8. Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Registration Year, 2011-2019
Figure 7.9. Clinical Trial Analysis: Distribution by Trial Status
Figure 7.10. Clinical Trial Analysis: Distribution by Phase of Development
Figure 7.11. Clinical Trial Analysis: Distribution by Patients Enrolled
Figure 7.12. Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2011-2019
Figure 7.13. Clinical Trial Analysis: Distribution by Popular Target Indications
Figure 7.14. Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 7.15. Clinical Trial Analysis: Distribution by Recruitment Status and Trial Registration Year
Figure 7.16. Clinical Trial Analysis: Distribution by Study Design
Figure 7.17. Clinical Trial Analysis: Leading Non-Industry Players by Number of Trials
Figure 7.18. Clinical Trial Analysis: Geographical Distribution by Number of Trials
Figure 7.19. Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Figure 7.20. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 7.21. Clinical Trial Analysis: Focus Areas
Figure 7.22. Steps Involved in the Process of Stool Donation
Figure 8.1. AC Matrix: Pictorial Representation
Figure 8.2. AC Matrix: Positioning of Different Indications
Figure 9.1. Big Pharma Players: Heat Map Analysis of Top Pharmaceutical Companies
Figure 9.2. Big Pharma Players: Analysis by Portfolio Diversity
Figure 9.3. Big Pharma Players: Analysis by Phase of Development
Figure 9.4. Big Pharma Players: Analysis by Type of Molecule
Figure 9.5. Big Pharma Players: Analysis by Type of Therapy
Figure 9.6. Big Pharma Players: Analysis by Diversity of Therapeutic Areas
Figure 9.7. Spider Web Analysis: Company A
Figure 9.8. Spider Web Analysis: Company B
Figure 9.9. Spider Web Analysis: Company C
Figure 9.10. Spider Web Analysis: Company D
Figure 9.11. Spider Web Analysis: Company E
Figure 9.12. Spider Web Analysis: Company F
Figure 9.13. Spider Web Analysis: Company G
Figure 9.14. Spider Web Analysis: Company H
Figure 9.15. Spider Web Analysis: Company I
Figure 9.16. Spider Web Analysis: Company J
Figure 9.17. Spider Web Analysis: Company K
Figure 10.1. Benchmark Analysis of Start-ups: Distribution by Portfolio Diversity
Figure 10.2. Benchmark Analysis of Start-ups: Distribution by Phase of Development
Figure 10.3. Benchmark Analysis of Start-ups: Distribution by Therapeutic Areas
Figure 10.4. Benchmark Analysis of Start-ups: Distribution by Funding Amount
Figure 10.5. Benchmark Analysis of Start-ups: Distribution by Number of Investors
Figure 10.6. Benchmark Analysis of Start-ups: Distribution by Progression in Funding
Figure 10.7. Benchmark Analysis of Start-ups: Distribution by Partnership Activity
Figure 10.8. Benchmark Analysis of Start-ups: Distribution by Patent Portfolio
Figure 10.9. Start-up Health Indexing: Roots Analysis Perspective
Figure 11.1. Diabetes: Diagnostic Limits for Plasma Glucose Levels
Figure 11.2. Non-Insulin Therapies for Diabetes
Figure 11.3. Weight Categories as per BMI Calculations
Figure 11.4. Causes of Obesity in Children
Figure 11.5. Obese Population: Distribution by Key Regions
Figure 12.1. Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
Figure 12.2. Funding and Investment Analysis: Cumulative Number of Instances by Year, 2013-2019
Figure 12.3. Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, 2013-2019
Figure 12.4. Funding and Investment Analysis: Cumulative Amount Invested, 2013-2019 (USD Million)
Figure 12.5. Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, 2013-2019 (USD Million)
Figure 12.6. Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2013-2019
Figure 12.7. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2013-2019 (USD Million)
Figure 12.8. Funding and Investment Analysis: Summary of Amount Invested, 2013-2019 (USD Million)
Figure 12.9. Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, 2013-2019 (USD Million)
Figure 12.10. Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, 2013-2019 (USD Million)
Figure 12.11. Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product, 2013-2019 (USD Million)
Figure 12.12. Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product and Funding Type, 2013-2019 (USD Million)
Figure 12.13. Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 12.14. Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, 2013-2019 (USD Million)
Figure 12.15. Funding and Investment Analysis: Distribution by Target Indication
Figure 12.16. Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication, 2013-2019 (USD Million)
Figure 12.17. Funding and Investment Analysis: Distribution by Geography
Figure 12.18. Funding and Investment Analysis: Regional Distribution of Funding Instances
Figure 12.19. Funding and Investment Analysis: Most Active Players by Number of Instances and Amount Invested, 2013-2019 (USD Million)
Figure 12.20. Funding and Investment Analysis: Most Active Investors by Number of Instances
Figure 12.21. Funding and Investment Analysis: Distribution by Type of Investors
Figure 12.22. Funding and Investment Analysis: Distribution by Location of Investors
Figure 12.23. Funding and Investment Summary, 2013-2019 (USD Million)
Figure 13.1. Microbiome Therapeutics Manufacturing Process
Figure 13.2. Challenges Related to Manufacturing Microbiome Therapeutics
Figure 13.3. Strategies to Optimize Microbiome Therapeutic Manufacturing Operations
Figure 13.4. Survey Respondents (December 2018): Distribution by Respondent Particulars
Figure 13.5. Microbiome Therapeutics: Distribution by Manufacturing Preference
Figure 13.6. Survey Respondents (June 2019): Distribution by Respondent Particulars
Figure 13.7. Microbiome Therapeutics: Distribution by Most Popular Analytical Techniques
Figure 14.1. Big Data: The Three V’s
Figure 14.2. Internet of Things: Framework
Figure 14.3. Internet of Things: Applications in Healthcare
Figure 14.4. Big Data: Google Trends
Figure 14.4. Big Data and Microbiome: Google Trends
Figure 14.5. Big Data: Key Application Areas
Figure 14.6. Big Data: Opportunities in Healthcare
Figure 14.7. Big Data: Key Benefits for Pharmaceutical and Biotechnology Products
Figure 14.8. Challenges Associated with Microbiome-related Big Data Management
Figure 15.1. Overall Microbiome Therapeutics Market, 2019-2030 (USD Billion)
Figure 15.2. Microbiome Therapeutics Market: Distribution by Type of Therapy, 2019 and 2030
Figure 15.3. Microbiome Therapeutics Market for Prescription Drugs, 2019-2030 (USD Million)
Figure 15.4. Microbiome Therapeutics Market for Prebiotic Drugs, 2019-2030 (USD Million)
Figure 15.5. Microbiome Therapeutics Market for Probiotic Drugs, 2019-2030 (USD Million)
Figure 15.6. Microbiome Therapeutics Market: Distribution by Type of Molecule, 2019 and 2030
Figure 15.7. Microbiome Therapeutics Market for Small Molecules, 2019-2030 (USD Million)
Figure 15.8. Microbiome Therapeutics Market for Biologics, 2019-2030 (USD Million)
Figure 15.9. Microbiome Therapeutics Market: Distribution by Target Indication, 2019 and 2030
Figure 15.10. Microbiome Therapeutics Market for Acne Vulgaris, 2019-2030 (USD Million)
Figure 15.11. Microbiome Therapeutics Market for Atopic Dermatitis, 2019-2030 (USD Million)
Figure 15.12. Microbiome Therapeutics Market for CDI, 2019-2030 (USD Million)
Figure 15.13. Microbiome Therapeutics Market for Colorectal Cancer, 2019-2030 (USD Million)
Figure 15.14. Microbiome Therapeutics Market for Crohn’s Disease, 2019-2030 (USD Million)
Figure 15.15. Microbiome Therapeutics Market for Dental Caries, 2019-2030 (USD Million)
Figure 15.16. Microbiome Therapeutics Market for Diabetes, 2019-2030 (USD Million)
Figure 15.17. Microbiome Therapeutics Market for IBS, 2019-2030 (USD Million)
Figure 15.18. Microbiome Therapeutics Market for Lactose Intolerance, 2019-2030 (USD Million)
Figure 15.19. Microbiome Therapeutics Market for Lung Cancer, 2019-2030 (USD Million)
Figure 15.20. Microbiome Therapeutics Market for NASH, 2019-2030 (USD Million)
Figure 15.21. Microbiome Therapeutics Market for Primary Hyperoxaluria, 2019-2030 (USD Million)
Figure 15.22. Microbiome Therapeutics Market for Psoriasis, 2019-2030 (USD Million)
Figure 15.23. Microbiome Therapeutics Market for Ulcerative Colitis, 2019-2030 (USD Million)
Figure 15.24. Microbiome Therapeutics Market for Others, 2019-2030 (USD Million)
Figure 15.25. Microbiome Therapeutics Market: Distribution by Therapeutic Area, 2019 and 2030
Figure 15.26. Microbiome Therapeutics Market for Autoimmune Disorders, 2019-2030 (USD Million)
Figure 15.27. Microbiome Therapeutics Market for Dental Disorders, 2019-2030 (USD Million)
Figure 15.28. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (USD Million)
Figure 15.29. Microbiome Therapeutics Market for Dermatological Disorders, 2019-2030 (USD Million)
Figure 15.30. Microbiome Therapeutics Market for Infectious Diseases, 2019-2030 (USD Million)
Figure 15.31. Microbiome Therapeutics Market for Metabolic Disorders, 2019-2030 (USD Million)
Figure 15.32. Microbiome Therapeutics Market for Oncology, 2019-2030 (USD Million)
Figure 15.33. Microbiome Therapeutics Market for Others, 2019-2030 (USD Million)
Figure 15.34. Microbiome Therapeutics Market: Distribution by Supply Channel, 2019 and 2030
Figure 15.35. Microbiome Therapeutics Market for Hospital Pharmacies, 2019-2030 (USD Million)
Figure 15.36. Microbiome Therapeutics Market for Retail Pharmacies, 2019-2030 (USD Million)
Figure 15.37. Microbiome Therapeutics Market for Online Pharmacies, 2019-2030 (USD Million)
Figure 15.38. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, 2019 and 2030
Figure 15.39. Microbiome Therapeutics Market in North America, 2019-2030 (USD Million)
Figure 15.40. Microbiome Therapeutics Market in Europe, 2019-2030 (USD Million)
Figure 15.41. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, 2019-2030 (USD Million)
Figure 15.42. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2019-2030 (USD Million)
Figure 15.43. Microbiome Therapeutics Market: Distribution by Leading Drugs, 2019-2030 (USD Million)
Figure 15.44. IBP-9414 (Infant Bacterial Therapeutics): Target Patient Population
Figure 15.45. IBP-9414 (Infant Bacterial Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 15.46. Oxabact® (OxThera): Target Patient Population
Figure 15.47. Oxabact® (OxThera): Sales Forecast, till 2030 (USD Million)
Figure 15.48. RBX2660 (Rebiotix): Target Patient Population
Figure 15.49. RBX2660 (Rebiotix): Sales Forecast, till 2030 (USD Million)
Figure 15.50. RP-G28 (Ritter Pharmaceuticals): Target Patient Population
Figure 15.51. RP-G28 (Ritter Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Figure 15.52. SER-109 (Seres Therapeutics): Target Patient Population
Figure 15.53. SER-109 (Seres Therapeutics): Sales Forecast, till 2030 (USD Million)
Figure 16.1. Overall Microbiome Diagnostics Market, 2019-2030 (USD Million)
Figure 16.2. Overall Microbiome Diagnostics Market, 2019-2030 (Units, Volume)
Figure 16.3. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-2030 (USD Million)
Figure 16.4. Microbiome Diagnostics Market for Crohn’s Disease, 2019-2030 (USD Million)
Figure 16.5. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (USD Million)
Figure 16.6. Microbiome Diagnostics Market for Diabetes, 2019-2030 (USD Million)
Figure 16.7. Microbiome Diagnostics Market for IBS, 2019-2030 (USD Million)
Figure 16.8. Microbiome Diagnostics Market for Lung Cancer, 2019-2030 (USD Million)
Figure 16.9. Microbiome Diagnostics Market for NASH, 2019-2030 (USD Million)
Figure 16.10. Microbiome Diagnostics Market for Obesity, 2019-2030 (USD Million)
Figure 16.11. Microbiome Diagnostics Market for Ulcerative Colitis, 2019-2030 (USD Million)
Figure 16.12. Microbiome Diagnostics Market: Distribution by Target Indications, 2019-2030 (Units, Volume)
Figure 16.13. Microbiome Diagnostics Market for Crohn’s Disease, 2019-2030 (Units, Volume)
Figure 16.14. Microbiome Diagnostics Market for Colorectal Cancer, 2019-2030 (Units, Volume)
Figure 16.15. Microbiome Diagnostics Market for Diabetes, 2019-2030 (Units, Volume)
Figure 16.16. Microbiome Diagnostics Market for IBS, 2019-2030 (Units, Volume)
Figure 16.17. Microbiome Diagnostics Market for Lung Cancer, 2019-2030 (Units, Volume)
Figure 16.18. Microbiome Diagnostics Market for NASH, 2019-2030 (Units, Volume)
Figure 16.19. Microbiome Diagnostics Market for Obesity, 2019-2030 (Units, Volume)
Figure 16.20. Microbiome Diagnostics Market for Ulcerative Colitis, 2019-2030 (Units, Volume)
Figure 16.21. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030 (USD Million)
Figure 16.22. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (USD Million)
Figure 16.23. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (USD Million)
Figure 16.24. Microbiome Diagnostics Market for Oncology, 2019-2030 (USD Million)
Figure 16.25. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, 2019-2030 (Units, Volume)
Figure 16.26. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, 2019-2030 (Units, Volume)
Figure 16.27. Microbiome Diagnostics Market for Metabolic Disorders, 2019-2030 (Units, Volume)
Figure 16.28. Microbiome Diagnostics Market for Oncology, 2019-2030 (Units, Volume)
Figure 16.29. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-2030 (USD Million)
Figure 16.30. Microbiome Diagnostics Market for Hospital Pharmacies, 2019-2030 (USD Million)
Figure 16.31. Microbiome Diagnostics Market for Retail Pharmacies, 2019-2030 (USD Million)
Figure 16.32. Microbiome Diagnostics Market for Online Pharmacies, 2019-2030 (USD Million)
Figure 16.33. Microbiome Diagnostics Market: Distribution by Supply Channel, 2019-2030 (Units, Volume)
Figure 16.34. Microbiome Diagnostics Market for Hospital Pharmacies, 2019-2030 (Units, Volume)
Figure 16.35. Microbiome Diagnostics Market for Retail Pharmacies, 2019-2030 (Units, Volume)
Figure 16.36. Microbiome Diagnostics Market for Online Pharmacies, 2019-2030 (Units, Volume)
Figure 16.37. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030 (USD Million)
Figure 16.38. Microbiome Diagnostics Market in North America, 2019-2030 (USD Million)
Figure 16.39. Microbiome Diagnostics Market in Europe, 2019-2030 (USD Million)
Figure 16.40. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (USD Million)
Figure 16.41. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, 2019-2030 (Units, Volume)
Figure 16.42. Microbiome Diagnostics Market in North America, 2019-2030 (Units, Volume)
Figure 16.43. Microbiome Diagnostics Market in Europe, 2019-2030 (Units, Volume)
Figure 16.44. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, 2019-2030 (Units, Volume)
Figure 17.1. Fecal Microbiota Therapies: Forecast Methodology and Key Assumptions
Figure 17.2. Overall FMT Market, 2019-2030 (USD Million)
Figure 17.3. Overall FMT Market, 2019-2030 (Units, Volume)
Figure 17.4. Overall Microbiome Market by Product Offerings: Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Billion)

List of Tables

Table 3.1. Types of Microbiota in the GI Tract
Table 3.2. Common Instances of Misuse of Antibiotics
Table 3.3. Impact of Antibiotics on Intestinal Microflora
Table 3.4. List of Microorganisms Classified as Class 1 Carcinogens by the IARC
Table 3.5. Relationship Between Microbiome and Disease
Table 3.6. Impact of Drug-Microbiome Interactions
Table 3.7. List of Foods Containing Prebiotics
Table 4.1. Microbiome Therapeutics: Clinical Pipeline
Table 4.2. Microbiome Therapeutics Clinical Pipeline: Information on Type of Molecule and Route of Administration
Table 4.3. Microbiome Therapeutics Clinical Pipeline: Additional Information
Table 4.4. Microbiome Therapeutics: Early-Stage Pipeline
Table 4.5. Microbiome Therapeutics Early-Stage Pipeline: Additional Information
Table 4.6. Microbiome Therapeutics: List of Drug Developers
Table 4.7. Microbiome Therapeutics: List of Discontinued Drugs
Table 4.8. Microbiome Therapeutics: List of Technology Platforms
Table 5.1. Blautix®: Current Status of Development
Table 5.2. 4D Pharma: Recent Developments and Future Outlook
Table 5.3. C16G2: Current Status of Development
Table 5.4. Armata Pharmaceuticals: Recent Developments and Future Outlook
Table 5.5. EDP1503: Current Status of Development
Table 5.6. Evelo Biosciences: Recent Developments and Future Outlook
Table 5.7. RBX2660: Current Status of Development
Table 5.8. Rebiotix: Recent Developments and Future Outlook
Table 5.9. SER-109: Current Status of Development
Table 5.10. SER-287: Current Status of Development
Table 5.11. Seres Therapeutics: Recent Developments and Future Outlook
Table 5.12. VE303: Current Status of Development
Table 5.13. VE416: Current Status of Development
Table 5.14. Vedanta Biosciences: Recent Developments and Future Outlook
Table 6.1. Microbiome Diagnostics: Marketed and Development Pipeline
Table 6.2. Microbiome Diagnostics: List of Developers
Table 6.3. Microbiome Screening / Profiling Tests: Marketed and Development Pipeline
Table 6.4. Microbiome Screening / Profiling Tests: List of Developers
Table 7.1. Comparison between Various Routes of Administration of FMT
Table 7.2. FMT: Summary of Clinical Guidelines
Table 7.3. FMT: Summary of Insurance Coverage Payer
Table 7.4. FMT: Marketed and Development Pipeline
Table 7.5. FMT: List of Developers
Table 7.6. FMT: List of Clinical Trials (Non-Industry Sponsored)
Table 7.7. Clinical Trial Analysis: Most Important Trials to Watch
Table 7.8. List of Stool Banks for FMT Development
Table 7.9. FMT and Human Microbiome Transplant (HMT): Key Differences in Processing
Table 7.10. Flora Medicine: FMT Treatment Cost
Table 7.11. OpenBiome: Types of FMT Formulations
Table 11.1. Diabetes: Current Treatment Options
Table 11.2. Diabetes: Side Effects of Current Treatment Options
Table 11.3. Microbiome Therapeutics Pipeline for Diabetes
Table 11.4. Microbiome Therapeutics Pipeline for Lactose Intolerance
Table 11.5. Microbiome Therapeutics Pipeline for NASH
Table 11.6. Microbiome Therapeutics Pipeline for Primary Hyperoxaluria
Table 11.7. Obesity: Side Effects of Current Treatment Options
Table 11.8. Microbiome Therapeutic Pipeline for Obesity
Table 11.9. Crohn’s Disease: Current Treatment Options
Table 11.10. Crohn’s Disease: Side Effects of Current Treatment Options
Table 11.11. Microbiome Therapeutics Pipeline for Crohn’s Disease
Table 11.12. IBS: Current Treatment Options
Table 11.13. Microbiome Therapeutics Pipeline for IBS
Table 11.14. Ulcerative Colitis: Current Treatment Options
Table 11.15. Ulcerative Colitis: Side Effects of Current Treatment Options
Table 11.16. Microbiome Therapeutics Pipeline for Ulcerative Colitis
Table 11.17. Colorectal Cancer: Side Effects of Current Treatment Options
Table 11.18. Microbiome Therapeutics Pipeline for Colorectal Cancer
Table 11.19. Lung Cancer: Current Treatment Options
Table 11.20. Lung Cancer: Side Effects of Current Treatment Options
Table 11.21. Microbiome Therapeutics Pipeline for Lung Cancer
Table 11.22. Acne Vulgaris: Current Treatment Options
Table 11.23. Acne Vulgaris: Side Effects of Current Treatment Options
Table 11.24. Microbiome Therapeutics Pipeline for Acne Vulgaris
Table 11.25. CDI: Diagnostic Testing
Table 11.26. CDI: Severity Scoring System and Treatment Options
Table 11.27. CDI: Side Effects of Current Treatment Options
Table 11.28. Microbiome Therapeutics Pipeline for CDI
Table 11.29. Bacterial Vaginosis: Current Treatment Options
Table 11.30. Bacterial Vaginosis: Side Effects of Current Treatment Options
Table 11.31. Microbiome Therapeutics Pipeline for Bacterial Vaginosis
Table 12.1. Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Funding Type, Year, Amount and Investor, till 2019
Table 12.2. Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Product, Target Indication and Focus Area, till 2019
Table 12.3. Microbiome Therapeutics and Diagnostics: Funding and Investments, Information on Type of Investor and Headquarter Location, till 2019
Table 13.1. List of Microbiome Contract Manufacturers: Information on Year of Establishment, Headquarters, Company Size and Type of Manufacturer
Table 13.2. List of Microbiome Contract Manufacturers: Information on Scale of Operation, Facility Location and Production Capacity
Table 13.3. List of In-House Microbiome Manufacturers: Information on Year of Establishment, Headquarters and Company Size
Table 13.4. List of CROs Offering Microbiome Research Services: Information on Year of Establishment, Headquarter and Company Size
Table 13.5. List of CROs Offering Microbiome Research Services: Information on Type of Services
Table 13.6. Comparison of Key Factors for the Selection of Contract Service Providers: Harvey Ball Analysis
Table 14.1. List of Companies Using Big Data for Microbiome Research
Table 14.2. Human Longevity: Partnerships and Collaborations
Table 14.3. Human Longevity: Venture Capital Funding
Table 14.4. Resilient Biotics: Venture Capital Funding
Table 15.1. Potential of Key Therapeutic Areas: Estimated Market Growth Rate
Table 15.2. Potential of Key Therapeutic Areas: Estimated Penetration (by 2030)
Table 15.3. Microbiome Therapeutics: Promising Drug Candidates
Table 15.4. Microbiome Therapeutics Forecast Assumptions: Price Estimations in Key Geographies
Table 15.5. IBP-9414 (Infant Bacterial Therapeutics): Net Present Value (USD Million)
Table 15.6. IBP-9414 (Infant Bacterial Therapeutics): Value Creation Analysis (USD Million)
Table 15.7. Oxabact® (OxThera): Net Present Value (USD Million)
Table 15.8. Oxabact® (OxThera): Value Creation Analysis (USD Million)
Table 15.9. RBX2660 (Rebiotix): Net Present Value (USD Million)
Table 15.10. RBX2660 (Rebiotix): Value Creation Analysis (USD Million)
Table 15.11. RP-G28 (Ritter Pharmaceuticals): Net Present Value (USD Million)
Table 15.12. RP-G28 (Ritter Pharmaceuticals): Value Creation Analysis (USD Million)
Table 15.13. SER-109 (Seres Therapeutics): Net Present Value (USD Million)
Table 15.14. SER-109 (Seres Therapeutics): Value Creation Analysis (USD Million)
Table 16.1. Microbiome Diagnostics Forecast Assumptions: Price Estimations in Key Geographies
Table 18.1. List of Companies Engaged in the Development of Microbiome Products for Other Applications
Table 18.2. Pipeline of Microbiome Based Consumer Products, Medical Foods and Supplements
Table 20.1. S-Biomedic: Company Snapshot
Table 20.2. Whole Biome: Company Snapshot
Table 20.3. Siolta Therapeutics: Company Snapshot
Table 20.4. Assembly Biosciences: Company Snapshot
Table 20.5. List Biological Laboratories: Company Snapshot
Table 20.6. Metabiomics: Company Snapshot
Table 20.7. Microbiome Therapeutics: Company Snapshot
Table 20.8. Universal Stabilization Technologies: Company Snapshot
Table 20.9. BiomX: Company Snapshot
Table 20.10. Da Volterra: Company Snapshot
Table 20.11. Chung Mei Pharmaceutical: Company Snapshot
Table 20.12. Pacific Northwest National Laboratories: Company Snapshot
Table 21.1. Microbiome Therapeutics Clinical Pipeline: Distribution by Phase of Development
Table 21.2. Microbiome Therapeutics Clinical Pipeline: Distribution by Type of Molecule
Table 21.3. Microbiome Therapeutics Clinical Pipeline: Distribution by Type of Therapy
Table 21.4. Microbiome Therapeutics Clinical Pipeline: Distribution by Target Indication
Table 21.5. Microbiome Therapeutics Clinical Pipeline: Distribution by Therapeutic Area
Table 21.6. Microbiome Therapeutics Clinical Pipeline: Distribution by Dosing Frequency
Table 21.7. Microbiome Therapeutics Clinical Pipeline: Distribution by Route of Administration
Table 21.8. Microbiome Therapeutics Clinical Pipeline: Distribution by Drug Formulation
Table 21.9. Microbiome Therapeutics Preclinical Pipeline: Distribution by Phase of Development
Table 21.10. Microbiome Therapeutics Preclinical Pipeline: Distribution by Type of Molecule
Table 21.11. Microbiome Therapeutics Preclinical Pipeline: Distribution by Type of Therapy
Table 21.12. Microbiome Therapeutics Preclinical Pipeline: Distribution by Target Indication
Table 21.13. Microbiome Therapeutics Preclinical Pipeline: Distribution by Therapeutic Area
Table 21.14. Microbiome Therapeutic Developers: Distribution by Year of Establishment
Table 21.15. Microbiome Therapeutic Developers: Distribution by Location of Headquarters
Table 21.16. Microbiome Therapeutic Developers: Distribution by Company Size
Table 21.17. Microbiome Therapeutic Developers: Distribution by Company Size and Location of Headquarters
Table 21.18. Microbiome Therapeutic Developers: Leading Drug Developers
Table 21.19. Ferring Pharmaceuticals: Annual Revenues, 2014-2018 (DKK Million)
Table 21.20. Seres Therapeutics: Annual Revenues, 2016-H1 2019 (USD Million)
Table 21.21. Microbiome Diagnostics: Distribution by Stage of Development
Table 21.22. Microbiome Diagnostics: Distribution by Type of Sample Required
Table 21.23. Microbiome Diagnostics: Distribution by Target Indication
Table 21.24. Microbiome Diagnostics: Distribution by Therapeutic Area
Table 21.25. Microbiome Diagnostics Developers: Distribution by Year of Establishment
Table 21.26. Microbiome Diagnostics Developers: Distribution by Location of Headquarters
Table 21.27. Microbiome Diagnostics Developers: Distribution by Company Size
Table 21.28. Microbiome Diagnostics Developers: Distribution by Company Size and Location of Headquarters
Table 21.29. Microbiome Diagnostics Developers: Leading Diagnostic Developers
Table 21.30. FMT: Distribution by Phase of Development
Table 21.31. FMT: Distribution by Therapeutic Area
Table 21.32. FMT: Distribution by Route of Administration
Table 21.33. FMT Developers: Distribution by Year of Establishment
Table 21.34. FMT Developers: Distribution by Location of Headquarters
Table 21.35. FMT Developers: Distribution by Company Size
Table 21.36. Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Registration Year, 2011-2019
Table 21.37. Clinical Trial Analysis: Distribution by Trial Status
Table 21.38. Clinical Trial Analysis: Distribution by Phase of Development
Table 21.39. Clinical Trial Analysis: Distribution by Patients Enrolled
Table 21.40. Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Trial Registration Year, 2011-2019
Table 21.41. Clinical Trial Analysis: Distribution by Popular Target Indications
Table 21.42. Clinical Trial Analysis: Distribution by Therapeutic Area
Table 21.43. Clinical Trial Analysis: Distribution by Recruitment Status and Trial Registration Year
Table 21.44. Clinical Trial Analysis: Distribution by Study Design
Table 21.45. Clinical Trial Analysis: Leading Non-Industry Players in Terms of Number of Trials Conducted
Table 21.46. Clinical Trial Analysis: Geographical Distribution by Number of Trials
Table 21.47. Clinical Trial Analysis: Geographical Distribution by Enrolled Patient Population
Table 21.48. Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 21.49. Diabetes: Diagnostic Limits for Plasma Glucose Levels
Table 21.50. Obese Population: Distribution by Key Regions
Table 21.51. Funding and Investment Analysis: Distribution by Type of Funding and Year of Establishment
Table 21.52. Funding and Investment Analysis: Cumulative Number of Instances by Year, 2013-2019
Table 21.53. Funding and Investment Analysis: Distribution by Type of Funding and Year of Investment, 2013-2019
Table 21.54. Funding and Investment Analysis: Cumulative Amount Invested, 2013-2019 (USD Million)
Table 21.55. Funding and Investment Analysis: Year-Wise Distribution by Amount Invested and Type of Funding, 2013-2019 (USD Million)
Table 12.56. Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2013-2019
Table 21.57. Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding, 2013-2019 (USD Million)
Table 21.58. Funding and Investment Analysis: Summary of Amount Invested, 2013-2019 (USD Million)
Table 21.59. Funding and Investment Analysis: Distribution by Total Amount Invested and Type of Company, 2013-2019 (USD Million)
Table 21.60. Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding, 2013-2019 (USD Million)
Table 21.61. Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product, 2013-2019 (USD Million)
Table 21.62. Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Product and Funding Type, 2013-2019 (USD Million)
Table 21.63. Funding and Investment Analysis: Distribution by Therapeutic Area
Table 21.64. Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area, 2013-2019 (USD Million)
Table 21.65. Funding and Investment Analysis: Distribution by Target Indication
Table 21.66. Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication, 2013-2019 (USD Million)
Table 21.67. Funding and Investment Analysis: Distribution by Geography
Table 21.68. Funding and Investment Analysis: Regional Distribution of Funding Instances
Table 21.69. Funding and Investment Analysis: Most Active Players by Number of Instances and Amount Invested, 2013-2019 (USD Million)
Table 21.70. Funding and Investment Analysis: Most Active Investors by Number of Instances
Table 21.71. Funding and Investment Analysis: Distribution by Type of Investors
Table 21.72. Funding and Investment Analysis: Distribution by Location of Investors
Table 21.73. Survey Respondents (December 2018): Distribution by Respondent Particulars
Table 21.74. Microbiome Therapeutics: Distribution by Manufacturing Preference
Table 21.75. Survey Respondents (June 2019): Distribution by Respondent Particulars
Table 21.76. Microbiome Therapeutics: Distribution by Most Popular Analytical Techniques
Table 21.77. Overall Microbiome Therapeutics Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.78. Microbiome Therapeutics Market: Distribution by Type of Therapy, Conservative, Base and Optimistic Scenarios, 2019 and 2030
Table 21.79. Microbiome Therapeutics Market for Prescription Drugs, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.80. Microbiome Therapeutics Market for Prebiotic Drugs, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.81. Microbiome Therapeutics Market for Probiotic Drugs, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.82. Microbiome Therapeutics Market: Distribution by Type of Molecule, Conservative, Base and Optimistic Scenarios, 2019 and 2030
Table 21.83. Microbiome Therapeutics Market for Small Molecules, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.84. Microbiome Therapeutics Market: Distribution by Target Indication, Conservative, Base and Optimistic Scenarios, 2019 and 2030
Table 21.85. Microbiome Therapeutics Market for Acne Vulgaris, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.86. Microbiome Therapeutics Market for Atopic Dermatitis, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.87. Microbiome Therapeutics Market for CDI, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.88. Microbiome Therapeutics Market for Colorectal Cancer, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.89. Microbiome Therapeutics Market for Crohn’s Disease, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.90. Microbiome Therapeutics Market for Dental Caries, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.91. Microbiome Therapeutics Market for Diabetes, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.92. Microbiome Therapeutics Market for IBS, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.93. Microbiome Therapeutics Market for Lactose Intolerance, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.94. Microbiome Therapeutics Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.95. Microbiome Therapeutics Market for NASH, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.96. Microbiome Therapeutics Market for Primary Hyperoxaluria, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.97. Microbiome Therapeutics Market for Psoriasis, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.98. Microbiome Therapeutics Market for Ulcerative Colitis, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.99. Microbiome Therapeutics Market for Others, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.100. Microbiome Therapeutics Market: Distribution by Therapeutic Area, Conservative, Base and Optimistic Scenarios, 2019 and 2030
Table 21.101. Microbiome Therapeutics Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.102. Microbiome Therapeutics Market for Dental Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.103. Microbiome Therapeutics Market for Digestive and Gastrointestinal Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.104. Microbiome Therapeutics Market for Dermatological Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.105. Microbiome Therapeutics Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.106. Microbiome Therapeutics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.107. Microbiome Therapeutics Market for Oncology, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.108. Microbiome Therapeutics Market for Others, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.109. Microbiome Therapeutics Market: Distribution by Supply Channel, Conservative, Base and Optimistic Scenarios, 2019 and 2030
Table 21.110. Microbiome Therapeutics Market for Hospital Pharmacies, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.111. Microbiome Therapeutics Market for Retail Pharmacies, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.112. Microbiome Therapeutics Market for Online Pharmacies, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.113. Microbiome Therapeutics Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenarios, 2019 and 2030
Table 21.114. Microbiome Therapeutics Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.115. Microbiome Therapeutics Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.116. Microbiome Therapeutics Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.117. Microbiome Therapeutics Market: Distribution by Leading Drug Developers, 2019-2030 (USD Million)
Table 21.118. Microbiome Therapeutics Market: Distribution by Leading Drugs, 2019-2030 (USD Million)
Table 21.119. IBP-9414 (Infant Bacterial Therapeutics): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.120. Oxabact® (OxThera): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.121. RBX2660 (Rebiotix): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.122. RP-G28 (Ritter Pharmaceuticals): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.123. SER-109 (Seres Therapeutics): Sales Forecast, till 2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 21.124. Overall Microbiome Diagnostics Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.125. Overall Microbiome Diagnostics Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.126. Microbiome Diagnostics Market: Distribution by Target Indications, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.127. Microbiome Diagnostics Market for Crohn’s Disease, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.128. Microbiome Diagnostics Market for Colorectal Cancer, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.129. Microbiome Diagnostics Market for Diabetes, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.130. Microbiome Diagnostics Market for IBS, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.131. Microbiome Diagnostics Market for Lung Cancer, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.132. Microbiome Diagnostics Market for NASH, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.133. Microbiome Diagnostics Market for Obesity, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.134. Microbiome Diagnostics Market for Ulcerative Colitis, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.135. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.136. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.137. Microbiome Diagnostics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.138. Microbiome Diagnostics Market for Oncology, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.139. Microbiome Diagnostics Market: Distribution by Therapeutic Areas, Conservative, Base and Optimistic Scenarios, 2019 -2030 (Units, Volume)
Table 21.140. Microbiome Diagnostics Market for Digestive and Gastrointestinal Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.141. Microbiome Diagnostics Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.142. Microbiome Diagnostics Market for Oncology, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.143. Microbiome Diagnostics Market: Distribution by Supply Channel, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.144. Microbiome Diagnostics Market for Hospital Pharmacies, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.145. Microbiome Diagnostics Market for Retail Pharmacies, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.146. Microbiome Diagnostics Market for Online Pharmacies, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.147. Microbiome Diagnostics Market: Distribution by Supply Channel, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.148. Microbiome Diagnostics Market for Hospital Pharmacies, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.149. Microbiome Diagnostics Market for Retail Pharmacies, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.150. Microbiome Diagnostics Market for Online Pharmacies, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.151. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.152. Microbiome Diagnostics Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.153. Microbiome Diagnostics Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.154. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.155. Microbiome Diagnostics Market: Distribution by Key Geographical Regions, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.156. Microbiome Diagnostics Market in North America, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.157. Microbiome Diagnostics Market in Europe, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.158. Microbiome Diagnostics Market in Asia-Pacific and Rest of the World, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.159. Overall FMT Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Million)
Table 21.160. Overall FMT Market, Conservative, Base and Optimistic Scenarios, 2019-2030 (Units, Volume)
Table 21.161. Overall Microbiome Market by Product Offerings, Conservative, Base and Optimistic Scenarios, 2019-2030 (USD Billion)

List of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

16S Technologies
4D Pharma
5QBD-Biotech
Aalborg University Hospital
Aarhus University
AB-Biotics
Abbott Laboratories
AbbVie
Abraxis BioScience
Academic Medical Centre (Amsterdam UMC)
ActoBio Therapeutics
Adapsyn Bioscience
Adare Pharmaceuticals
AdvancingBio
AEProbio
Aetna
AgBiome
Ajuvis Labsd
Alaven Pharmaceutical
Aleris-Hamlet Hospital
Alimentary Health (Part of PrecisionBiotics Group)
Alimentary Pharmabiotic Centre Microbiome Institute, University College Cork (UCC)
Allergan
Allergy Therapeutics
Altis Biosystems
Amabiotics
Amazon
American College of Gastroenterology
Ample
AmpliPhi Biosciences
Amrita Therapeutics
Anavex Life Sciences
AnimalBiome
ANIZOME
AOBiome Therapeutics
Ardigen
Arena Pharmaceuticals
Arizona State University
Armata Pharmaceuticals
Artizan Biosciences
ARTPred
Ascus Biosciences
Asia Microbiota Bank
AsiaBiome (formely known as Civet Biosciences)
Assaf Harofeh Medical Center
Assembly Biosciences
APHM (Public Assistance - Marseille Hospitals)
APHP (Public Assistance - Paris Hospitals)
Astarte Medical
Astel Medica
AstraZeneca
Atlas Biomed
Autonomous University of Nuevo León
Aventis Pharma
AvidBiotics
Axcan Pharma
Axial Biotherapeutics
Azitra
Bactana
Bayer
Baylor College of Medicine
Becton Dickinson
Beiersdorf
Beth Israel Deaconess Medical Center
Bio Farma
Biocartis
Biocodex
BioControl (Acquired by Merck)
BioGaia
Biogen
Biohit Healthcare
BIOHM Health
Bio-K Plus International
Biom Pharmaceuticals
BioMathematica
BiomCare
Bio-Me
Biome Makers
Biome360
BiomeBliss
Biomecite Diagnostics
BiomeSense
Biomica (subsidiary of Evogene)
Biomillenia
BiomX
BioRankings
Biorasi
biose
Biotagenics
Blis Probiotics
Blue Biology
Blue Turtle Bio
Boehringer Ingelheim
BoobyBiome
Boston Children’s Hospital
Boston Medical Center
Brigham and Women's Hospital
Bristol-Myers Squibb
BugSpeak
Caelus Health
California Institute of Technology (Caltech)
Campus Bio-Medico University
Canadian Association of Gastroenterology
Canadian Institutes of Health Research
Capsugel
Captozyme
Carbiotix
CARB-X
Careggi University Hospital
Case Comprehensive Cancer Center
Catholic University of the Sacred Heart
Cedars-Sinai Medical Center
Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology
Center of Food and Fermentation Technologies
Centers for Disease Control and Prevention
CHAIN Biotechnology
Charles River Laboratories
Children's Hospital Los Angeles
Children's Hospital of Philadelphia
Children's Mercy Hospital Kansas City
Chr. Hansen
Chugai Pharmaceutical
Chung Mei Pharmaceutical
ChunLab
Cigna
CIPAC Healthcare
Clasado BioSciences
ClearB Therapeutics
Clinical Investigation Center for Innovative Technology Network
Clinical Microbiomics
ClostraBio
Cobra Biologics
Commense (a subsidiary of PureTech Health)
Concentric Ag
Cook MyoSite
CoreBiome
Cornell University
CosmosID
Covaris
CRB-HUEP
Crohn's & Colitis Foundation
CRS Bio
Cykinso
Dairy & Food Culture Technologies
Dakota BioTech
Danisco
Da Volterra
Dayanand Medical College & Hospital
DayTwo
DermBiont
Diagnostic Solutions Laboratory
Diversigen
DNA Genotek
Duke University
DuPont
Eagle Genomics
Eat Troo
Eatrics
Edico Genome (Acquired by Illumina)
EirGenix
Eli Lilly
ELiE Health Solutions
Embion Technologies
EmblemHealth
Emory University
Emulate
Englewood Health
Enterin
EnteroBiotix
Enterome Bioscience
EpiBiome (Acquired by Locus Biosciences)
Esse Skincare
European Commission
European Society of Clinical Microbiology and Infectious Diseases
Evelo Biosciences
Evolve BioSystems
Evotec
EXDEN
Exeliom Biosciences (formerly known as Nextbiotix)
EzBioCloud
Fecal Microbiota Transplantation Workgroup
Federal Research and Clinical Center of Physical-Chemical Medicine
FermBiotics
Ferring Pharmaceuticals
Finch Therapeutics
First Affiliated Hospital of Chengdu Medical College
Flora Medicine
Floragraph
First Affiliated Hospital of Nanchang University
Fortify
Foundation of Hope
Fourth Military Medical University
Frontier Science & Technology Research Foundation
FUJIFILM Diosynth Biotechnologies
Fuzhou General Hospital
G.D Searle
Galderma
Gallinée
GALT
Genetic Analysis
Institute of Molecular Genetics Academy of Sciences Czech Republic
GENEWIZ
Genome and Company
Genova Diagnostics
Genten Therapeutics
German Federal Ministry of Education and Research
Ghent University
GI Innovation
Ginkgo Bioworks
Global Cosmetics
GNUbiotics Sciences
GoodBelly
GoodGut
Groken Bioscience
GlaxoSmithKline
GT Biologics
Guangzhou First People's Hospital
Gülhane Institute of Health Sciences
Gusto Global
Hadassah Medical Center
Hamilton Health Sciences
Harvest Capital Strategies
Haukeland University Hospital
Health Net
HealthPartners
University of Helsinki
Hoechst Marion Roussel
Holobiome
Hospital District of Helsinki and Uusimaa
Hospital for Sick Children
Hospital Ramón y Cajal
Hudson Institute of Medical Research
Human Longevity
Hunter Holmes McGuire Veterans Administration Medical Center
Hvidovre Hospital
Hy Laboratories
Hyggut
IBM
Icahn School of Medicine at Mount Sinai
iCarbonX
Igen Biolab Group
ImClone Systems
ImmuneBiotech
Immunex
Immuron
Indiana University
Indigo Therapeutics
Inserm
Institut Allergosan
Institut national de la recherche agronomique
Institute for Clinical and Experimental Medicine
The Institute of Animal Physiology
Institute of Liver and Biliary Sciences
Intralytix
Intrexon
Intuition Biosciences
Invivo Healthcare
Ipsat Therapies
Ironwood Pharmaceuticals
IS-Diagnostics
Island Health
Isohelix
ISOThrive
Ixcela
Ixion Biotechnology
J. Craig Venter Institute
Janssen Biotech
Jena University Hospital
Jinling Hospital
John Theurer Cancer Center
Johnson & Johnson
Joint Authority for Päijät-Häme Social and Health Care
Juno Bio
Kaleido Biosciences
Kallyope
Karolinska Institutet
Kelsey Research Foundation
Keystone Bio
King's College London
Kingston Health Sciences Centre
Kintai Therapeutics
KNOMICS MICROBIOTA
Kobiolabs
La Trobe University
Laboratorio Cobas
Lactobio
Lallemand Health Solutions
Lavie Bio
Lawrence Berkeley National Laboratory
Lawson Health Research Institute
Leadiant Biosciences
Leiden University
Lesaffre Human Care
Levanger Hospital
List Biological Laboratories
LNC Therapeutics
Locus Biosciences
London Health Sciences Centre
Lonza
Lovisenberg Diakonale Hospital
LUCA Biologics
Luina Bio
Luxia Scientific
M.D. Anderson Cancer Center
MaaT Pharma
Madison University
Maiden Therapeutics
Mankind Pharma
Manufacturer Vilhelm Pedersen Foundation
Marqués de Valdecilla University Hospital
Masonic Cancer Center
Massachusetts General Hospital
Massachusetts Institute of Technology
MatriSys Bioscience
Mayo Clinic
McMaster University
MD Anderson Cancer Center
Medeva Pharmaceuticals
Medical College of Wisconsin
Medical University of Graz
Medlab
Memorial Medical Center Foundation
Memorial Sloan Kettering Cancer Center
Memorial University of Newfoundland
MemorialCare Health System
Merck
Merge Healthcare
Metabiomics
MetaboGen
Michael E. DeBakey Veterans Affairs Medical Center
Mitchell Cancer Institute
Microba
Microbiome Diagnostic Partners
Microbiome Health Research Institute
Microbiome Insights
Microbiome Research Centre
MicroBiome Therapeutics
Microbiome Therapeutics Innovation Group
MicrobiomeDx
Microbiotica
Microinventa
Microsoft
Microviable Therapeutics
Millennium Pharmaceuticals
Miomics
Miyarisan Pharmaceutical
Modena University Hospital
Molzym
Monash University
Montefiore Medical Center
Moon Biotech
Mount Sinai Hospital
mybacs
MyBiotics
MyMicroZoo
NAFLD Research Center, University of California San Diego School of Medicine
Naked Biome
Nantes University Hospital
National Cancer Institute (NCI)
The National Institute for Health and Care Excellence (NICE)
National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute for Health and Medical Research (INSERM)
National Institutes of Health (NIH)
National Jewish Health
National PKU Alliance
Nationwide Children's Hospital
Nestlé Health Science
New York University
New Zealand Society of Gastroenterology
NIZO
Nordland Hospital Trust
NorthShore University HealthSystem
Norway Regional Health Authority
Norwegian University of Science and Technology
Novartis
Novo Nordisk
Novogene
Novome Biotechnologies
Nubiyota
Open Patient data Explorative Network
Odense University Hospital
Ohio State University Wexner Medical Center
Omega Biomics
One Codex
OpenBiome
OptiBiotix
Oragenics
Oralta
Orebro University
Oregon State University
Orexigen Therapeutics
Osel
OSI Pharmaceuticals
Oslo University Hospital
OxThera
Pacific Northwest National Laboratory (PNNL)
Paragon Bioservices (unit of Catalent Biologics)
Parker Institute for Cancer Immunotherapy
Vlaamse Parkinson Liga
Parkinson's Institute and Clinical Center
Peking Union Medical College Hospital
Pendulum Therapeutics (formerly known as Whole Biome)
Perrigo
Persona Biome
Pfizer
Pharmacia & Upjohn
Pharm-Olam
Phase Genomics
Phi Therapeutics
Phylagen
Pierre and Marie Curie University
Pierre Fabre
Pillar Healthcare
Postbiotics Plus
Postgraduate Institute of Medical Education and Research
PrecisionBiotics
Presutti Laboratories
Prime Discoveries
Priority Health
Probiotical
ProdermIQ
ProDigest
Prometheus Laboratories
PSI Foundation
Psoriasis Association
Psychiatric Hospital of the University of Basel
Public Health England
Public Health Ontario
Puerta de Hierro University Hospital
Qiara
Qingdao Institute of Bioenergy and Bioprocess Technology
Quadram Institute
Quay Pharma
Queen Elizabeth II Health Sciences Centre
Queen's University
Quorum Innovations
Quotient Sciences
Rambam Healthcare Campus
Rebiotix (part of Ferring Pharmaceuticals Group)
Regence BlueShield
Regeneron Pharmaceuticals
Replete Biotics
Research Foundation - Flanders
Research Institute of St Joe’s Hamilton
Resilient Biotics
Resphera Biosciences
Rise Therapeutics
Ritter Pharmaceuticals
Roche
RondinX (Acquired by BiomX)
Roswell Park Comprehensive Cancer Center
Ruprecht Karl University of Heidelberg
Rush University
Sabinsa
Saint-Antoine Hospital
Salix Pharmaceuticals
Sanofi
S-Biomedic
Scaled Microbiomics
SciBac
Scioto Biosciences
Seattle Children's Hospital
Second Genome
Seed Health
Santa Maria della Misericordia Hospital
Seres Therapeutics
SFA Therapeutics
Shanghai Children's Medical Center
Shanghai General Hospital
Shanghai Jiao Tong University School of Medicine
Shanghai Zhongshan Hospital
Sheba Medical Center
Shoreline Biome
Sicor
Siffra Farmaceutici
Sinai Health System
Siolta Therapeutics
Sjogren’s Syndrome Foundation
SkinBioTherapeutics
Snipr Biome
Solarea Bio
Soroka Medical Center
SRZ Properties
St. Justine's Hospital
Stanford Cancer Institute
Stanford University School of Medicine
Stony Brook University
Sucampo Pharmaceuticals
Sugarlogix
Sun Genomics
Symberix
Symbiota
Symbiotix Biotherapies
Syneos Health
Synergy Worldwide
Synlogic
Synthetic Biologics
Synthetic Genomics
Taiho Pharmaceutical
Takeda Pharmaceutical
TargEDys
Tel Aviv Sourasky Medical Center
Temple University
Teva Pharmaceutical
Texas Digestive Diseases Center
Texas Children’s Hospital
The BioCollective
The Chinese University of Hong Kong
The Danish Rheumatism Association
The Flanders Institute for Biotechnology
The Jackson Laboratory
The Miriam Hospital
The Research Council of Norway
The Second Affiliated Hospital of Nanjing Medical University
The University of Texas Health Science Center
The University of Texas MD Anderson Cancer Center
The Weston A Price Foundation
Thryve Digital
Tongji Hospital
Toronto Invasive Bacterial Diseases Network
Tortuga Biosciences
Trayer Biotherapeutics
Triphase Pharmaceuticals
TULA Skincare
uBioDiscovery
uBiome
UCB Pharma
Umeå University
Universitair Ziekenhuis Leuven
University Health Network
University Hospital Cologne
University Hospital of Limoges
University Hospital of North Norway
University of Adelaide
University of Alberta
University of British Columbia
University of Calgary
University of California
University of Chicago
University of Chieti
University of Florence
University of Maryland
University of Massachusetts
University of Melbourne
University of Miami
University of Minnesota
University of Modena and Reggio Emilia
University of New South Wales
University of North Carolina
University of North Texas
University of Oslo
University of Pennsylvania
University of Pittsburgh
University of Portsmouth
University of Southern Denmark
University of Surrey
University of Texas
University of Toronto
University of Tromso
University of Vermont
University of Wisconsin
University of Zurich
US Army Medical Research and Materiel Command
US Department of Veterans Affairs
VA Office of Research and Development
Vaiomer
Vancouver General Hospital
Varinos
Vast Biome
Vedanta Biosciences
Vertex Pharmaceuticals
Viome
Virginia Commonwealth University
Visbiome
ViThera Pharmaceuticals
Vitrilife
Vivus
WACKER (formerly known as Synco Bio)
Washington University School of Medicine
Weill Cornell Medical College of Cornell University
Wellmicro
Western Sydney Local Health District
Westmead Institute for Medical Research
Winclove Probiotics
Wolfson Medical Center
Women's College Hospital
Xbiome
Xycrobe Therapeutics
Yakult Honsha
Yonsei University
Zehna Therapeutics
ZMD Group

Segmentation

Over USD 4 billion (by 2030) financial opportunity within the microbiome therapeutics (Tx) market and diagnostics (Dx) markets, has been analyzed across the following segments:

Type of Therapy (Tx)

Prescription Drug
Prebiotics
Probiotics

Type of Molecule (Tx)

Small Molecules
Biologics

Target Indication (Tx+Dx)

Acne Vulgaris
Atopic Dermatitis
Clostridium difficile Infection
Colorectal Cancer
Crohn’s Disease
Diabetes
Irritable Bowel Syndrome
Lactose Intolerance
Lung Cancer
Nonalcoholic steatohepatitis (NASH)
Obesity
Ulcerative colitis

Therapeutic Area (Tx+Dx)

Autoimmune Disorders
Dental Disorders
Digestive and Gastrointestinal Disorders
Dermatological Disorders
Infectious Disease
Metabolic Disorders
Oncology
Others

Supply Channel (Tx+Dx)

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Key Geographical Regions (Tx+Dx)

North America
Europe
Asia-Pacific and Rest of the World

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

Single-User License USD 4,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

Site License USD 7,999

This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

Enterprise License

USD 15,999

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.net

Microbiome

The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030

Example Insights

Overview

Scope of the Report

Contents

Chapter Outlines

Table of Contents

List of Figures

List of Tables

List of Companies

Segmentation

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

Single-User License USD 4,899

Site License USD 7,999

OUR CLIENTS

YOU MAY ALSO LIKE

COVID-19 Impact on Gene Therapy Market

COVID-19 Vaccine: Do We Have Enough Manufacturing Capacity?

License	Price
Single-User License This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print multiple copies, solely for your use. Under this agreement, the report (either full or in part) should not be redistributed or reproduced in any form. Unless a Site License or an Enterprise License is purchased, a Single User license must be purchased for every person that wishes to use the report within the same enterprise.	USD 4,899
Site License This license grants the right of use of the purchased report by the employees of a business unit at a particular site / office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple copies for use by employees at the same location. Apart from this, the report (either full or in part) should not be redistributed or reproduced in any form. It is the buyer’s responsibility to ensure that the report is kept secure and isn’t made available to any third party.	USD 7,999
Enterprise License This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm / enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the maximum number of prints which can be taken. However, it is the buyer’s responsibility to ensure that the report is kept secure and isn’t made available to any third party.	USD 15,999

LOGIN

Forgot Password

Microbiome

The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030

Example Insights

Overview

Scope of the Report

Contents

Chapter Outlines

Table of Contents

List of Figures

List of Tables

List of Companies

Segmentation

Request Customization

Please select a suitable option for customization in the report

PRICING DETAILS

Single-User License USD 4,899

Site License USD 7,999

OUR CLIENTS

YOU MAY ALSO LIKE

Novel coronavirus (COVID-19): Preventive Vaccines, Therapeutics and Diagnostics in Development

Non-Viral Transfection Reagents and Systems Market, 2020-2030

Companion Diagnostics Development Services Market, 2020-2030

SUBSCRIBE TO INDUSTRY UPDATES

COVID-19 Impact on Gene Therapy Market

COVID-19 Vaccine: Do We Have Enough Manufacturing Capacity?